b e h r n g e r n g e l h e annual report value innovationf n ci l h gh l ig h ts um ar r ep r amounts eur million unless otherwise indicated change net sales region europe americas u r asia australia africa r e p r business human pharmaceuticals animal health biopharmaceuticals discontinued operations research development personnel expenses average number employees operating income operating income net sales group profit loss net sales group equity return group equity investments tangible assets depreciation tangible assets top products human pharmaceuticals top products animal health net sales millions eur change net sales millions eur change spiriva nexgard pradaxa frontline jardiance ingelvac ciroflex trajenta jentadueto heartgard v e r v e w core leitbild group management report consolidated financial statements product portfolio company improving health quality life patients goal researchdriven pharmaceutical company boehringer ingelheim focus diseases satisfactory treatment option exists date company therefore concentrates developing inn ovative therapies extend patients lives animal health boehringer ingelheim stands advanced prevention familyowned since established boehringer ingelheim one pharmaceutical industrys top companies employees create value innovation daily three business areas human pharmaceuticals animal health biopharmaceuticals boehringer ingelheim generated net sales around billion euros rd expenditure almost billion euros corresponded per cent net sales familyowned company boehringer ingelheim plans generations focuses longterm success rather shortterm profit company therefore aims organic growth resources simultaneous openness partnerships strategic alliances research everything boehringer ingelheim naturally adopts responsibility towards mankind environmentc n e n core leitbild shareholders perspective key aspects corporate bodies group management report information group report economic position report opportunities risks report expected developments consolidated financial statements overview selected consolidated companies consolidated balance sheet consolidated profit loss statement cash flow statement statement changes group equity notes consolidated financial statements independent auditors report product portfolio human pharmaceuticals respiratory diseases cardiovascular metabolic diseases oncology diseases central nervous system infectious diseases tiergesundheit livestock swine livestock cattleruminants livestock poultry veterinary public health vph companion animals horse companion animals pets sharehlders perspective shareholders perspective shareholders perspective successful year boehringer ingelheim success us means reached patients thereby delivered significant contribution human animal health favourable figures company documents annual report also testify success primary objective remains maintain boehringer ingelheims indepen dence order sustainable continue remain competitive need innovations readiness invest competition average research development production innovative medicines follows knowledge time mirrors trust place boehringer ingelheim employees high degree commitment decisive success shared guiding principles leitbild goal improving health humans animals bind us together worldwide individuality characterises culture values stand familyowned company boehringer ingelheim help us maintain independence express thanks go employees together contributed great engagement effort realise corporate goals signed christian boehringer chairman shareholders committeet h e b r f n g n g r e c r allan hillgrove michel pairet hubertus von baumbacht h e b r f n g n g r e c r michael schmelmer andreas neumann joachim hasenmaier key aspects employees worldwide share enthusiasm task improving health humans animals innovation therapeutic breakthroughs today want tell realise shared vision results able achieve past year year successful one boehringer ingelheim reason focus innovation large number research projects currently human pharmaceuticals pursue approaches want first therapeutic class indication us also decisive conduct research areas unmet medical needs patients dependent innovations focus already principle foundation success boehringer ingelheim many decades provided basis growth human pharmaceuticals business last year although expiry market exclusivity marked impact development biggest products overall able grow line local markets frequently even outgrow considerably thanks great therapeutic progress offered new pro ducts ofev jardiance animal health area concluded integration process merged organisations prioritising customer needs ahead optimisation already enabled us exceed market growth year two new structure biopharmaceuticals business also developing favourably particular progress expanding capacity vienna austria today already visible large extent numerous partnerships reinforce innovative core equally business areas across whole value chain shown well specific competences third parties combine boehringer ingelheims special capabilities translate patient benefit accom panying magazine highlights transformation takes detailed look possibili ties digitalisation offers us dear reader past financial year successful one boehringer ingelheim also charac terised continual change previous years basis trust customers partners especially commitment employees sense responsibility entrepreneurial spirit helped us remain competitive deserve thanks signed signed signed hubertus von baumbach joachim hasenmaier allan hillgrove signed signed signed andreas neumann michel pairet michael schmelmer corporate bodies shareholders committee board managing directors christian boehringer hubertus von baumbach chairman shareholders committee chairman board managing directors christoph boehringer dr joachim hasenmaier member board managing directors erich von baumbach jr animal health isabel boehringer allan hillgrove member board managing directors dr mathias boehringer human pharma prof dr dr andreas barner dr andreas neumann member board managing directors human resources advisory board dr michel pairet member board managing directors egbert appel innovation chairman advisory board trustee martin hilti family trust michael schmelmer president hilti foundation member board managing directors finance dr nikolaus von bomhard former chairman board management mnchener rckversicherungsgesellschaft ag dr andreas kreimeyer former member board executive directors research executive director basf se jan rinnert chairman board managing directors heraeus holding gmbhpage g r u p n g e e n r e p r tpage g r u p n g e e n r e p r information group groups business model research development production occupational safety environmental protection employee reporting social responsibility report economic position macroeconomic environment earnings position development businesses financial position net assets position report opportunities risks opportunities risk management individual risks overall statement risk situation report expected developments troper tnemeganam puorg boehringer ingelheim annual report group management report information group groups business model years boehringer ingelheim pursued goal improving preserving quality life health humans animals headquartered ingelheim rhein germany com pany familyowned since founding among leading companies world wide industry one germanys researchintensive companies boehringer ingelheim concentrates particular researching medicines offering therapies diseases satisfactory treatment options currently unavailable provides entire value chain starting reasearch development rd production commercialisation products boehringer ingelheim operates global level around employees areas human pharmaceuticals animal health biopharmaceuticals generated net sales almost eur billion human pharmaceuticals companys medicines already standard treatments various therapeutic areas represent core focus boehringer ingelheims activities integration merial following transaction january containing swap boehringer ingelheims consumer successfully completed health care business sanofis animal health business merial integration new compa nies successfully completed merger boehringer ingelheims existing animal health activities merial companys animal health business market leader germany global level secondlargest provider veterinary vaccines medicines unmesta tszearllsees n abchy g besuchsifntene sins group eur million biopharmaceuticals sales eur million eur million animal health human pharmaceuticals eur million eur million group management report net sales region eur million europe asia australia africa aaa americas boehringer ingelheim continues expand existing product portfolio organic growth including cooperation external partners recent acquisition companys global research network expanded countries major facilities germany biberach han ingelheim us ridgefield connecticut duluth georgia st joseph missouri austria vienna well japan kobe france lyon companys biggest revenue contributor human pharmaceuticals business spiriva still biggest spiriva used treat chronic obstructive pulmonary disease copd asthma revenue contributor following products also made significant contributions boehringer ingelheims success pradaxa used prevent strokes patients atrial fibrillation prevention treatment thromboembolic disorders type diabetes products jardiance winner prix galien inter national innovative pharmaceutical product trajenta medicine ofev latter medicine introduced offers people rare fatal respiratory dis ease idiopathic pulmonary fibrosis ipf first time treatment option companys animal health business antiparasitic nexgard strongest product terms net sales antiparasitics heartgard frontline established swine vaccine ingelvac circoflex used treat porcine circovirus type also played key role success companys animal health business biopharmaceuticals business another important growth area boehringer ingelheim boehringer ingelheims biopharmaceutical activities comprise manufacture ownbrand market able products actilyse metalyse praxbind one worlds leading com panies process development commercial production biopharmaceuticals thirdparty industrial customers laicnanif detadilosnoc stnemetats boehringer ingelheim annual report financial year boehringer ingelheim achieved majority sales americas europe regions region asiaaustraliaafrica aaa strategic significance groups future growth making sales three biggest markets usa japan germany accounted sales research development line mission statement boehringer ingelheims goal research develop innovative medicines therapies treatment diseases currently satisfactory treatments available key emphasis developing pharmaceuticals well new approaches therapies prevent detect treat chronic diseases effectively focus making major contribution areas need treatment high taking leading position human pharmaceuticals business well field animal health research development expenditure eur million net sales human pharmaceuticals expenditure eur million human pharmaceuticals net sales average number employees investments tangible assets without investments infrastructure eur million rely partnerships academic institutions biotech companies public research institu tions well global research network comprising facilities many different countries around world moreover field development projects technologies research activ ities supplemented important cooperation licence agreements boehringer ingelheim continued expand research network acquisition viratherapeutics gmbh represents significant addition rd immunooncological therapies based use oncolytic viruses area cardiovascular studies examining effect empagliflozin launched cooperation eli lilly companys rd portfolio already broad supplemented partnerships key component boehringer ingelheims innovation strategy complement innovative prowess rd also evidence boehringer ingelheims successful collaboration third parties also seen online portal opnme gives researchers worldwide opportu nity order molecules boehringer ingelheim use without fear infringing patents researchers unique opportunity start experiments continue research addition joint research projects developed new findings drug development generated group management report rd sites animal health ah human pharmaceuticals hp americas europe asia oceania brazil germany australia paulnia ah biberach hp sydney ah hanover ah mexico ingelheim ah china guadalajara ah katharinenhofrohrdorf ah shanghai ah taizhou ah usa denmark ames ah kalundborg ah japan athens colbert ah kobe hp duluth ah france tokyo ah fulton ah lyon ah gainesville ah saint vulbas ah new zealand north brunswick ah auckland ah ridgefield hp italy saint joseph ah milan hp sioux center ah netherlands lelystad ah austria vienna hp second year existence boehringer ingelheims digital laboratory bi x employees digital laboratory bi x experts digital technologies currently working five innovative digital products last year innovation driver two successfully handed respective business past year petpro con nect app connects pet owners vets usa collaboration platform research ers ntc studio boehringer ingelheims rd activities basis companys sustainable success inno vative capability played key role groups positive business development past years inhouse rd supplemented external cooperation partnerships also continue top priority future laicnanif detadilosnoc stnemetats boehringer ingelheim annual report financial year employed average people rd facilities total almost eur billion invested rd new medicines corresponding around groups net sales slightly level expected human pharmaceuticals respiratory since century committed improving lives people living diseases respiratory diseases scientific research new therapeutic concepts help patients need continues high importance boehringer ingelheim focus areas chronic obstructive pulmonary disease copd cystic fibrosis cf idiopathic pulmonary fibrosis ipf systemic sclerosis interstitial lung disease sscild well forms progressive fibrosing interstitial lung diseases pfild early results landmark dynagito trial published lancet respiratory data week trial show people copd tiotropiumolodaterol lowers rate moderatetosevere exacerbations compared tiotropium monotherapy results contribute understanding copd exacerbations role dual combination bronchodilator lamalaba therapy management copd another focus topic importance physical activity people living copd number studies completed published investigated effect tiotropumolodaterol compared tiotropium monotherapy physical activity related endpoints towards end year started receive first national approvals new enhanced respimat inhaler launched first european countries starting first quarter european respiratory society international congress presented final data two important trials idiopathic pulmonary fibrosis ipf inpulsison trial instage trial results inpulsison indicate safety efficacy nintedanib ipf maintained four years consistent prior findings inpulsis study programme instage trial showed efficacy safety nintedanib patients ipf severe impair ment gas exchange usually excluded clinical trials consistent observed patients less advanced disease earlier trials trials published highranking med ical journals lancet respiratory new england journal medicine respectively addi tion communicating new scientific data key effort raise awareness need diagnose treat ipf early possible together various stakeholders partners remains key challenge affected patients boehringer ingelheim became founding member open source imaging consortium osic statement commitment advancing science supporting innovation ben efit patients goal osic develop digital imaging biomarkers accurate imagingbased diagnosis prognosis prediction response therapy ipf fibrosing interstitial lung diseases ilds group management report scleroderma systemic sclerosis ssc continued efforts support patients create awareness rare disease scleroderma campaign senscis trial inves tigating safety efficacy nintedanib patients systemic sclerosisassociated ild completed patients recruited largest randomised placebo controlled clinical trial ssc date results presented inbuild trial evaluating efficacy safety nintedanib weeks patients pro gressive fibrosing interstitial lung disease pfild ongoing trial includes range patients diagnosed interstitial lung disease except ipf exhibit similar progressive fibrosing phenotype ie deterioration respiratory symptoms lung function worsening fibrosis chest imaging irrespective underlying diagnosis unique basket approach makes inbuild trial including patients different underlying diseases varied chronic hyper sensitivity pneumonitis rheumatoid arthritis associated ild sarcoidosis approach based underlying hypothesis response lung injury patients includes development fibrosis becomes progressive selfsustaining independent initiating trigger results expected course boehringer ingelheim committed fighting cancer provide patients new treatment oncology options dedicated collaborating oncology community shared journey deliver leading science goal firstinclass treatments breakthrough potential transform lives patients help win fight cancer focus discovering developing accelerating novel therapeutic approaches address unmet needs lung gastrointestinal cers end conducting targeted research therapies immunooncology products intelligent combination approaches offer greatest chance success fight cancer successfully advanced several research programmes clinical development strengthen oncology portfolio actively seeking scientific collaborations inno vative partnerships strategic acquisitions goal improve understanding cancer transform patient lives commitment innovation already resulted important treat ments lung cancer afatinib giotrifgilotrif nintedanib vargatef afatinib giotrifgilotrif secondgeneration egfr inhibitor treatment specific type nonsmall cell lung cancer nsclc patients metastatic nsclc squamous histology available patients since become standard care many markets approved indications results giotag realworld study investigate use frontline afatinib followed nextline targeted treatment extend chemotherapyfree treatment time patients first published study shows using afatinib giotrifgilotrif fol lowed osimertinib thirdgeneration egfr inhibitor provides median months chemo therapyfree regimen patients egfr mutationpositive nsclc results add com prehensive luxlung trial programme afatinib nine trials including head head randomised trials versus firstgeneration treatments boehringer ingelheims second marketed cancer drug vargatef nintedanib treatment advanced nonsmall cell lung cancer nsclc combination docetaxel patients pre viously treated chemotherapy december results realworld study vargado showed nintedanib plus docetaxel could option failure immunotherapy patients nintedanib combination chemotherapy also investigated patients malig nant pleural mesothelioma mpm epitheloid histology rare aggressive type cancer laicnanif detadilosnoc stnemetats boehringer ingelheim annual report strongly associated exposure asbestos data respective phase iii trial lumemeso presented showed nintedanib combination standard chemotherapy extend progressionfree survival patients mpm cardiovascular boehringer ingelheims therapeutic area cardiovascular metabolic diseases contains metabolic diseases companys core products within diabetes portfolio specifically jardiance empagliflozin important research data published range new clinical trials collaborations announced march boehringer ingelheim diabetes alliance partner eli lilly announced plans expand clinical trial programme empagliflozin chronic heart failure emperial rials trials evaluate effect empagliflozin exercise ability heart failure symptoms people chronic heart failure independent whether type diabetes april diabetes alliance initiated empakidney clinical trial investigates effects empagliflozin progression kidney disease occurrence cardiovascular death peo ple established chronic kidney disease without diabetes study independently conducted analysed reported medical research council population health research unit university oxford mrc phru summer data ease phase iii programme investigating use empagliflozin combination insulin therapy adults type diabe tes published randomised controlled trials met primary endpoint based total ity ease data boehringer ingelheim initiated regulatory discussions empagliflozin adjunct insulin adults type diabetes european medicines agency ema committee medicinal products human use chmp issued positive opinion july update labels jardiance empagliflozin synjardy empagliflozin metformin glyxambi empagliflozin linagliptin include additional important data landmark empareg outcome trial heart failure kidney endpoints labels also include results relative risk reduction hospitalisation heart failure relative risk reduction newonset worsening kidney disease empagliflozin compared placebo people type diabetes established cardiovascular disease european association study diabetes easd congress october results carmelina first two cardiovascular outcome trials dpp inhibitor linagliptin trajenta presented carmelina studied impact linagliptin cardiovascular kid ney safety adults type diabetes high risk heart andor kidney disease study met primary endpoint linagliptin demonstrating similar cardiovascular safety profile compared placebo added standard care carmelina also included key secondary composite endpoint showing similar kidney safety profile compared placebo results second cardiovascular outcome trial carolina expected carolina evaluates impact treatment linagliptin compared sulphonylurea glimepiride top standard care cardiovascular safety patients early type diabetes increased cardiovascular risk estab lished cardiovascular complications group management report shortly easd congress american diabetes association ada easd published consensus report recommending sglt inhibitors empagliflozin help manage cardiovas cular outcomes patients type diabetes empagliflozin sglt inhibitor recom mended ada standards medical care diabetes reducing risk cardiovascular death people type diabetes established cardiovascular disease following announce ment american college cardiology acc published new expert consensus decision pathway ecdp also recommending empagliflozin preferred sglt inhibitor proven benefit reducing risk cardiovascular death adults type diabetes established cardiovascular disease worldwide treatment guidelines updated include findings empareg outcome trial endorsement type diabetes treatments proven cardiovascular benefits october journal circulation published analysis based data empareg outcome trial suggests treatment empagliflozin positively impacts life expectancy adults type diabetes established cardiovascular disease using actuarial methods assuming demonstrated beneficial effects empagliflozin remain consistent longterm use empagliflozin estimated extend life expectancy years average depending age compared placebo american heart association aha scientific sessions november initial effectiveness results first realworld evidence study empagliflozin emprise presented reinforcing clinical results landmark empareg outcome trial finally conclude highly successful year diabetes products jardiance empagliflozin awarded international prix galien best pharmaceutical product award prestig ious honour field pharmaceutical research innovation recognising outstanding efforts achievements pharmaceutical rd also successful year pradaxa october company presented primary results two key trials respectesus respect cvtat world stroke congress montreal canada respectesus first trial investigate dabigatran etexilate versus acetylsalicylic acid asa full results trials expected published primary analyses contribute scientific communitys understanding diseases add wealth evidence support ing established safety profile pradaxa important neuropsychiatric diseases schizophrenia alzheimers disease diseases well depression continue centre boehringer ingelheims research central nervous central nervous system diseases many companies institutions pulled cns projects past years system cns reason many players field setbacks seem frequent successes boehringer ingelheim remain true motto commitment never stops opti mistic develop effective therapies treatment neuropsychiatric diseases laicnanif detadilosnoc stnemetats boehringer ingelheim annual report highly complex diseases like schizophrenia focus investigating impaired glutama tergic signalling pathway present range cns diseases based findings clinical trial schizophrenia investigating particular specific mechanism action could used prevent deterioration first psychotic episode prevent relapses schizophrenia studies effect glyt inhibition cognitive impairment alzheimers disease schizo phrenia track expect phase ii clinical results within beyon clinical trials depression investigating effect substance influence hyperactivity certain brain regions responsible impaired processing negative stimuli started substances investigated earlier stages development immunology boehringer ingelheim continuously developing immunology rd activities years ramping capacities series dermatological gastroenterological indications initial clinical testing results published september field dermatology suggest positive therapeutic potential active substance bi interleukin receptor antagonist rare form psoriasis known generalised pustular psoriasis patients clearly visible inflammatory skin diseases palmoplantar pustulosis ppp neurodermitis atopic dermatitis frequently face considerable disruptions lives since skin changes painful also visible series active substances rorgamma inhibitor currently clinical development stage showing initial signs offering strong therapeutic potential patients various immunological diseases boehringer ingelheims development programme includes substances treatment chronic inflammatory bowel diseases crohns disease ulcerative colitis also lupus nephritis strong yet unmet medical need effective therapies last year development substance risankizumab treatment psoriasis originally resulted research activities completed partnership abbvie abbvie submitted substance regulatory authorities development marketing partner ship abbvie offers best means ensuring first interleukin inhibitor emerge boehringer ingelheims research programme made available greatest possible number patients broadbased pipeline substantial investments immunology boehringer ingelheim expects significantly contribute better treatment patients immune diseases foreseeable future assume sole responsibility development marketing activities group management report animal health rd work field animal health boehringer ingelheim concentrates innovative vaccines antiparasitics protection livestock pets well pharmaceutical products treatment chronic diseases facilities europe asia oceania north central south america focus research new drugs development future therapeutic solutions since many vaccines based local pathogens pathogen variants imperative present key market regions local rd production facilities past year invested approximately eur million new rd plants expansion existing facilities lyon portedesalpes france completed construction eur million research building employees order bring rd activities vaccine production together single facility another milestone spatial consolidation research activities china eur million investment expansion research centre investments demonstrate commitment strengthen animal health means innovative preventive medicines intention sustainably expand leading position field initiated clinical studies worldwide received product authorisations addition internal rd analyse external projects products integrate portfolio appropriate obtaining approvals expanding geographical distri bution existing products important aspects rd activities biopharmaceuticals decided pursue biosimilars activities including potential partnerships within us market end development activities markets concentrating launching approved biosimilar cyltezo adalimumabadbm us market laicnanif detadilosnoc stnemetats boehringer ingelheim annual report production facilities animal health ah human pharmaceuticals hp biopharmaceuticals bio americas europe italy asia oceania brazil denmark fornovo hp china itapecerica hp kalundborg ah noventa ah nanchang ah paulnia ah shanghai hp bio germany netherlands taizhou ah mexico biberach hp bio lelystad ah guadalajara ah dortmund hp indonesia xochimilco hp ingelheim hp austria bogor hp vienna bio puerto rico france japan barceloneta ah lyon ah spain yamagata hp saintherblon ah malgrat hp usa toulouse ah sant cugat hp new zealand athens ah auckland ah columbus hp greece united kingdom fremont bio koropi hp pirbright ah gainesville ah st joseph ah production human pharmaceuticals human pharmaceuticals business production responsible reliable supply innova tive topquality medicines competitive prices patients customers ongoing development companys internal production facilities strategic cooperation external manufac turers established modern flexible market supply network encompasses entire value chain suppliers starting materials worldwide logistics distribution finished pharma ceutical products group management report global network included boehringer ingelheims plants countries group four biopharmaceuticals facilities also three plants manufacture active pharmaceutical ingredients well plants manufacture finished pharmaceutical products facilities boehringer ingelheims production facilities concentrate products strategic countries human importance company well stateoftheart cases unique manufacturing tech pharmaceuticals nologies partnerships external manufacturers expand production capacities focus prod ucts already far advanced terms life cycle within scope companys redesigned network increasing amounts produced com panys antidiabetic product portfolio transferred facilities throughout world thus assuming increasingly important role instance production capacity increased active pharmaceutical ingredients fornovo italy finished pharmaceutical products koropi greece xochimilco mexico company also initiated additional important investments development transformation capacities internal external network ingelheim headquarters company began implement key investment industrialisa tion newly developed medicines initial market supply medicines sant cugat facility spain company made progress construction plant supply market respimat technologybased inhalation medicines time end product life cycle aggrenox company closed biberach sites dedicated production plant alongside continued development companys production network ongoing development value chain management another current area focus implementation companys supply chain strategy set motion process transformation spanning entire value chain supplier customer endtoend goal highly integrated flexible delivery chain fully transparent efficiently controlled modern digital technology animal health following acquisition merial teams two companies working together create environment promises future success boehringer ingelheim animal health operated network facilities countries dedicated manufacture vaccines animal health facilities finished pharmaceutical products nutraceuticals industrial setup complemented con countries tract manufacturers primarily north central america well europe defined new network strategy order balance internal external production subsequently integra tion merial focus core products full alignment business requirements addition production facility paulnia brazil past year invested new production line strong revenue contributor nexgard barceloneta puerto rico facility moreover produc tion vaccines footandmouth disease expanded global level boehringer ingelheim established collaboration two chinese partners aiming triplication production much soughtafter vaccine laicnanif detadilosnoc stnemetats boehringer ingelheim annual report biopharmaceuticals one leading boehringer ingelheim pursues biopharmaceutical activities facilities biberach germany companies vienna austria fremont california usa shanghai china comprise manufacture industrial customers ownbrand marketable products actilyse metalyse praxbind manufacture biopharmaceuticals clinical testing one worlds market leaders process develop ment launch preparation commercial production biopharmaceuticals thirdparty industrial customers top pharmaceutical companies innovative biotech firms clients boehringer ingelheims biopharmaceuticals business boehringer ingelheim covers entire biophar maceutical value chain genetic development production cell followed manufacturing active substance filling finished pharmaceutical product product launch global market supply saw overall increase almost full use capacity network industrialscale production facilities besides many products boehringer ingelheim fulfilled biberach germany facility increasing level market demand actilyse chinese market particular com panys facility fremont california usa third largescale bioreactor launched market product customer transferred thus possible meet rising product demand within network biberach germany fremont california usa moreover largescale cell culture plant biberach germany largescale microbial plant vienna aus tria two customer products successfully approved international authorities expansion project new industrialscale biopharmaceutical production facility boehringer ingel heims site vienna austria reached milestone toppingout ceremony facil ity took place autumn companys commercial filling facility shanghai china also successfully put operation local market countries outside china production delivery began scheduled gmp hospital products finished pharmaceutical products addition application approval customer product chinese authorities successfully completed another important milestone terms chinese authorities recognition shanghai facility contract manufacturer cmo occupational safety environmental protection protection employees environment well sustainable use natural resources promotion environmental awareness major components groups mis sion statement prime importance boehringer ingelheim compliance social environmental aspects firmly anchored corporate philosophy many years ensure achieve sustainability future generations groupwide long established binding standards terms environmental protection health safety work internal guidelines reflect respective countryspecific require ments many cases go far beyond standards prescribed law particular follow international standards guidance documents work close cooperation relevant associations within boehringer ingelheim corporate department environment health safety sustainability ehss responsible particular strategic focus group management report boehringer ingelheim continued characterised integration sanofis animal health division merial group addition safety environmental risk assessments new facilities integration audits implemented training platform ehs academy established order provide employees ehss training develop awareness field technical support regular ehss audits boehringer ingelheims internal facilities premises suppliers contract manufacturers ensure compliance well international standards company continuously reviews status environmental protection health safety work potential improvement identified basis us close coordination stakeholders within outside company extremely impor tant advancing current topics relevant company taking stand formu lating related position papers order achieve continuous sustainable improvements world wide sake company topics range use improved refrigerants use certified natural resources careful handling plastics boehringer ingelheim supports united nations un sustainable development goals sdgs well development corresponding iso standards making contribution sustaina bility th un climate change conference katowice poland conference parties cop ehss representatives boehringer ingelheim participated contribution towards reducing global greenhouse gas emissions continue pursue goal activities futher reducing entire co e emissions compared values achieve co reduction goal make futureoriented reductions environmental footprint overall interna tional green initiative stepped activities planned rollout safe safety initiative aims reduce number workplace accidents also continued successful workshops focus behaviourbased safety held several companys worldwide facilities high five safety initiative defines five simple rules behaviour shall ensure improved occupational safety laicnanif detadilosnoc stnemetats boehringer ingelheim annual report employee reporting boehringer ingelheim employed people average worldwide represents increase previous year number staff increased regions additional employees average number employees region americas europe asiaaustraliaafrica aaa major success factor positive growth group engaged motivated staff accord ingly particularly committed actively developing supporting employees order best prepared challenges ahead part comprehensive training system empha sise acquisition technical expertise also promote social skills integration various experiences cultural backgrounds personalities boehringer ingel heim creates openness different approaches opinions living corporate vision value innovation global company important us diversity markets reflected workforce creating working environment embraces diversity differences one pillars corporate culture boehringer ingelheim contributing factor companys success addition competitive salaries boehringer ingelheim offers benefits employees benefits include range company pension plans flexible homebased work options numer ous healthrelated benefits significant segment corporate strategy part talent management departments remit ensure employability staff promote wide range opportunities innovation work motivate employees nurture talents develop individuals vocational training always major importance boehringer ingelheim part standing social responsibility company offers career opportunities great number young apprentices people time also tie talented wellqualified workforce young professionals germany company backdrop demographic change young professionals started careers boehringer ingelheim germany different scientific technical com mercial fields training dualstudy courses december young people enrolled vocational training programme germany one companys aims strengthen appeal boehringer ingelheim top employer current future employees boehringer ingelheim recipient various awards efforts area received top marks auditors international independent top employers institute categories salaries compensation benefits employee development performance management received distinction facilities germany well facilities china taiwan brazil russia spain poland first time singa pore number country organisations awarded rating unprecedented group management report evidence strong appeal development opportunities company employees potential recruits social responsibility taking social responsibility also important aspect corporate culture commitment wellbeing patients employees families focus range projects addition support people need various initiatives countries regions active company companys activities also focus protecting maintaining environment previous years boehringer ingelheim continues assist providing support integra tion people fled home country pursues broad range measures area boehringer ingelheim employees germany conducting workshops refugees addition company partnership deutsche universittsstiftung partnership boehringer ingelheim sponsors welcome scholarship programme supports students crisis regions company also helps candidates c risis regions areas people fleeing join company offering apprenticeships opportunity complete introductory training year internship upon successfully completing internships employees offered permanent positions past year major pillar social commitment making health mmh initiative since start making health continuously developed social entrepreneurship movement within com worldwide initiative pany externally socially entrepreneurial sustainable activities limited individual projects relating various regions issues instead initiative focuses creatively connecting local international partners different sectors networking across traditional visible invisible borders central element successful social movement order identify pro mote implement innovative solutions farreaching complex challenges health care sector cocreation bridge social commercial entrepreneurship brings together social entrepreneurs nonprofit organisations health care sector boehringer ingel heim employees resources date within mmh network boehringer ingelheim ashoka one worlds largest nonprofit organisations together helped around social entrepreneurs reach approximately million people worldwide area health care mmh initiative also aims promote employees commitment social entrepreneurship order advance health care projects many different countries working local external partners well colleagues throughout boehringer ingelheim mmh leadership programmes rural south ern india insights india participation online social intrapreneurship courses opportunities col laborate social entrepreneurs mmh network executives residence internal competition promoting employees projects honed staffs social entrepreneurial think ing activities also strengthened networking philosophy partnerships nonprofit organisations social enterprises health care sector large number local pro jects taken place employees actively involved improving health means understanding peoples environment everyday challenges offering solutions needed health awareness affordability accessibility health services acceptance play key role mmh plays role university sector goal helping students lecturers learn socially entrepreneurial thinking practical activities development health carerelated projects laicnanif detadilosnoc stnemetats boehringer ingelheim annual report angels initiative together european stroke organisation eso world stroke organisation wso stroke alliance europe safe many national stroke associations companies boehringer ingelheim established unique health initiative goal initi ative improve stroke care europe emerging markets hospitals already part angels initiative november initiative received prestigious health collaboration award service delivery category european federation pharmaceu tical industries associations efpia boehringer ingelheim established introduced lastmile programme support global alliance livestock veterinary medicines galvmed funding bill melinda gates foundation integrated solutionoriented initiative aims respond critical challenges field animal health ensuring consistent availability medical resources animals hardtoaccess areas subsaharan africa initiative currently focuses ruminants sheep goats cattle expanded include poultry project boehringer ingel heim helps small farmers africa gain access veterinary medicines underlines boehringer ingelheims strong social commitment aim positive impact human animal lives areas particularly vital need boehringer ingelheim values respects employees differences actively promotes diverse cooperative open working environment conscious fact diversity mar kets customers reflected workforce us diversity makes right mix inclusion brings best results mix therefore focus encouraging inclusive environment kind diversity thrive boehringer ingelheim participated th german diversity day motto fly flag diversity two largest german facilities ingelheim biberach official member diversity charter since early prout employer acknowledged prout work foundation since group management report report economic position macroeconomic environment line worldwide economic growth rate slightly likewise registered eurozone economic output grew less strongly growth rate emerging markets developing countries level previous year slightly due growth slowdown major economies reduction global growth expected next years continuously expanding emerging markets developing countries unable make usa result increasing private consumption well investments intellectual property production wells oil gas industry secondlongest growth phase past years continued strongly expansionary fiscal policy form tax reform start also stim ulated economic output time increasing funding deficit tariff increases resolved usa start countertariffs introduced affected trading partners response negative impact economic growth although economic repercus sions relatively limited due low proportion overall trade volume japan worlds thirdlargest economy recorded decline gross domestic product first quarter year despite consistently low unemployment rate followed eight consecutive quarters growth nevertheless economy managed grow throughout year however strongly attributable high rate utilisation existing capacities well decrease growth exports chinese economy continues undergo process structural transformation whereby ser vice sector asserting comparison manufacturing sector chinese economys rate growth remains strong driven governments high growth targets however weakened slightly compared previous years also attributable restrictive market access condi tions foreign companies china well external trade political tensions usa economic performance steadily increased asian region whole due strong economic growth emerging markets developing countries particular global scale however emerging markets developing countries provided grounds concern argentina tur key relatively serious current account deficits significant debt levels high inflation rates triggered devaluation countries currencies however far limited countries since emerging markets hold high foreign currency reserves terms economic momentum eurozone recorded negative development due attenuation foreign trade ended exportdriven boom past years lack qualified personnel technical capacities resulted supplyside bottlenecks manufacturing industries particular addition factors ongoing discussion introduction tariffs certain product groups well eus postbrexit economic relationship united kingdom negatively affected sentiment eurozone hand unem ployment rate remained unchanged eurozone despite economic downturn inflation picked course year due rising energy prices wage costs laicnanif detadilosnoc stnemetats boehringer ingelheim annual report german economy continued grow past year though trend weakened appreciably summer end year reasons included production losses due strikes illness well problems german automotive industry weaker level demand eurozone world economys loss impetus present enduring problems additional adverse effect foreign demand already negatively affected economic conditions inflation germany averaged thus close ecbs target level prices increased strongly compared previous years due aboveaverage increase price food luxury food items tobacco beer sharply increased prices heating oil petrol global economic upturn expected weaken one hand reflects fact many advanced economies already exhausted production capacities also experiencing recruitment difficulties hand expected usas restrictive mon etary policy result significantly worse financing terms latin america decelerate pace economic growth addition positive effect usas tax reform gradually recede background currency development effect net sales average rate basis eur eur million usd jpy cny gbp cad brl global pharmaceuticals market registered growth financial year iqvia global use medicine outlook trend driven rising demand industrialised countries cancer medicines products treatment autoimmune diseases antidiabetic medicines due ageing population industrialised countries industrys growth remained stable surpassed growth previous year group management report earnings position longterm sustainably successful development forms basis securing companys independence long term combined stable earnings sound financing core boehringer ingelheims strategic focus previous years based approach principles boehringer ingelheim recorded net sales eur million financial year corre eur sponds decrease compared previous years level eur million exchange rate developments foreign exchange markets associated exchange rate effects negative impact sales growth biggest markets billion net sales currency adjusted groups growth rate stood leaving aside discontinued operations interim contracts agreements signed early following exchange busi nesses sanofi contributed significantly sales operating sales com panys core business areas adjusted currency effects grew sales eur million share around overall sales americas region remains boehringer ingelheims key sales market slight decline sales resulted negative currency effects north south america originary sales growth north america could offset currencyadjusted basis sales americas region increased compared previous year europe region registered net sales eur million thus contributed groups net sales corresponds decline sales compared decrease largely consequence lower previousyear sales discontinued operations currency effects significant impact asiaaustraliaafrica aaa region realised slight growth currencyadjusted basis net sales declined particularly japan net sales eur million achieved region corresponding share almost groups total revenues net sales region eur million currency change adjusted americas europe asiaaustraliaafrica aaa general sales growth conformed expectations supported good results clinical trials well external partners able place promising new products market successfully push ahead wellestablished products hand experiencing increasingly difficult market situation constantly challenging market access growing price pressure key markets overall company asserted well despite difficult condi tions laid foundations future growth laicnanif detadilosnoc stnemetats boehringer ingelheim annual report materials ratio taking consideration change inventory improved resulted negative impact previous year sales merial companies inventories assessed market value addition relatively lowmargin service production agreements discontinued operations consumer health care business longer included personnel expenses increased due increased number employees plus expenses pension plans similar obligations depreciation amortisation also increased mainly attributable writedown intangible assets animal health business well impairment losses tangible assets france spain operating income included extraordinary effects totalled eur million eur million mainly due restructuring measures integration costs overall despite positive operating trend core business operating income thus line previous years level considering extraordinary effects met expectations boehringer ingelheim recorded operating income eur million corresponding return sales percentage points previous years return sales key figures eur million change net sales operating income return net sales income taxes income taxes na income taxes increased eur million mainly due improved holding income financial result reflects increased interest expenses due pension commitments similar obli gations well losses plan assets previous year included gains plan assets financial result improved tax expenses negatively affected significant extraordinary effects resulting disposal consumer health care business well tax reform usa negative factors longer applicable therefore report clearly positive income tax must noted regard provisions german commercial law shareholders per sonal taxes arising group business activities may recognised tax expenses instead taxes presented part withdrawals group equity taking specificity account actual tax ratio markedly higher figure shown profit loss statement eur despite difficult market conditions adverse currency effects boehringer ingelheim registered positive development operating business financial year following previous year shaped integration processes extraordinary tax effects concluded past year billion income income taxes eur million eur million taxes group management report development businesses past financial year boehringer ingelheims business activities divided areas human pharmaceuticals animal health biopharmaceuticals net sales businesses eur million currency change adjusted human pharmaceuticals animal health biopharmaceuticals sales discontinued operations human pharmaceuticals around total group revenue human pharmaceuticals main pillar boehringer ingelheims business activities net sales business amounted eur million equivalent change currency adjusted compared previous year growth currency positive currencyadjusted sales growth resulted particular successful placement adjusted human innovative products well solid market position established medicines pharmaceuticals emerging markets us market key growth drivers human pharma ceuticals business hand many significant markets price pressure particularly established medicines relatively strong euro represent difficult environment boehringer ingelheim nonetheless managed assert product spiriva used treat chronic obstructive pulmonary disease copd biggest contributor sales generated revenues eur million reporting period previous years level eur million result increasing price pressure boehringer ingelheims secondstrongest product terms sales anticoagulant pradaxa registered sales eur million past year increase compared financial year type diabetes medicine jardiance winner prix galien inter national innovative pharmaceutical product recorded strong growth achieved sales eur million jardiance reporting period corresponds increase compared previous years eur million laicnanif detadilosnoc stnemetats boehringer ingelheim annual report net sales eur million change spiriva pradaxa jardiance trajenta jentadueto regard regional distribution sales human pharmaceuticals business usa share far largest market boehringer ingelheim generated sales eur million corresponds increase compared previous year currencyadjusted secondbiggest market eucan region europe canada australia new zealand accounted revenues eur million sales increased compared eur mil lion exchange rate effects significant influence sales trend japan sales declined eur million eur million partly due expiry cooperation agreement product micardis net sales region eur million change usa europecanadaaustralianew zealand eucan emerging markets japan strong sales increase growth markets sales increased eur million currencyadjusted sales growth markets previous year amounted eur million china growth almost achieved compared resulting sales eur million group management report animal health sales products animal health business increased amounted eur million thus currencyadjusted higher net sales eur million change nexgard frontline ingelvac circoflex heartgard financial year reporting period three antiparasitics vaccine ingelvac growth driven circoflex companys four best selling medicines antiparasitics product nexgard generated strongest sales revenues eur million eur million thus recording growth compared previous year followed another antiparasitic frontline registered decrease eur million eur million due adverse currency effects product ingelvac circoflex used vaccine porcine circovirus type achieved eur million sales financial year represents decline previous year eur million net sales region eur million change north america europe africaasiamiddle eastoceania metasia latin america biopharmaceuticals financial year biopharmaceuticals business maintained position industrial customers segment order situation entire business developed p ositively resulting strong growth high capacity utilisation biopharmaceutical production sales increased eur million biopharmaceuticals eur million laicnanif detadilosnoc stnemetats boehringer ingelheim annual report financial position eur million financial funds cash flow operating activities cash flow investing activities cash flow financing activities change financial funds cash relevant transactions change financial funds due change consolidated companies exchange rate movements financial funds boehringer ingelheims financial management instruments methods aimed securing liquid ity minimising financial risks optimising cost capital appropriate capital structure financial activities therefore geared towards supporting business strategy cash flow operating activities amounted eur million represents increase eur million comparison previous year eur million cash flow investing activities declined considerably eur million eur million prior year strongly affected cash settlement swap businesses sanofi tax payments resulting sale consumer health care business significant investments investments particular importance boehringer ingelheim strategic point view con tinuous investment requirement longterm development company forms basis profitable growth business activities total eur million invested tangible intangible assets year review representing unchanged high level slight increase compared eur million furthermore eur million deposited plan assets pension similar obligations mainly usa toppingout ceremony autumn expansion production vienna austria strongly growing biopharmaceutical business represents biggest single investment tory boehringer ingelheim well underway jobs created alone eur million invested facility significant site group decades important investment also took place business human pharmaceuticals despite dis posal chemical production site malgrat spain beginning whose new proprietor future incorporated production network external strategic partner spain remains important site boehringer ingelheim group eur million invested project comprises production cartridges used respimat products filling well packaging global distribution sant cugat spain group management report important investment made animal health business march groundbreaking new production facility focus production avian vaccines begun lyon portedesalpes france expected offer employment people invest ment follows rising demand vaccines footandmouth disease resulting higher poultry consumption cash outflow financing activities amount eur million mainly includes payments shareholders interest paid overall taking currency effects changes within group consolidated companies consideration led increase boehringer ingelheim groups financial funds eur million eur million net assets position eur million change change assets intangible tangible assets financial assets fixed assets inventories trade accounts receivable receivables current assets cash cash equivalents current assets assets total assets equity liabilities group equity provisions pensions similar obligations tax provisions provisions accounts payable loans greater years liabilities liabilities difference capital consolidation total equity liabilities laicnanif detadilosnoc stnemetats boehringer ingelheim annual report financial year boehringer ingelheims total assets amounted eur million increase eur million compared previous year significant reason development financial funds rose eur million result positive cash flow increase deferred tax assets working capital trade receivables inventories fixed assets contributed rise well despite depreciation amortisation impairments high investment activity initial consolida tion viratherapeutics gmbh positive currency effects led slight increase tangible intangible assets around financial assets also went around due reversal impairment loss previous year inventories trade receivables grew significantly eur million result higher working capital usa emerging markets especially china japan receivables current assets decreased mainly due lower tax prepayments usa france ger many increase assets arose higher deferred tax assets based temporary differ ences fixed assets well higher plan assets pensions similar obligations usa increased equity ratio increase group equity eur million result group profit well spite higher positive currency effects surpassed withdrawals shareholders group equity balance sheet total december amounted eur million equity ratio improved december addition equity pension provisions longterm liabilities also groups disposability long term total three items amounted eur mil lion representing share total assets consequently longterm disposable capital covers intangible tangible assets well working capital pension provisions increased due higher actuarial interest rate utilisation updated mortality tables provisions discounts guarantees usa tax provisions germany went comparison previous reporting year well trade accounts payable liabilities banks slightly decreased liabilities increased due higher tax liabilities germany liabilities declined mainly due reversal difference capital consolidation lower deferred tax liabilities temporary differences fixed assets boehringer ingelheims positive development financial year also reflected net asset position boehringer ingelheim remains soundly financed profitable company group management report report opportunities risks opportunities risk management assessing risks context holistic opportunities risk management also endeav take account resulting opportunities opportunities management based strat egies objectives company individual businesses operating business units integral part groupwide planning management systems responsible busi nesses functions bear direct responsibility early systematic identification analysis use opportunities boehringer ingelheim researchdriven innovative pharmaceutical company current rd activities considered relevant opportunity relevant projects already illustrated research development chapter aim risk management system implemented boehringer ingelheim identify busi nessspecific risks particular risks jeopardise continued existence company early possible assess reduce reasonable level means suitable measures persons responsible key businesses functions well included process calculating assessing risks groupwide risk information system ensures identified risks analysed assessed carefully following appropriate classification various catego ries adequate risk management measures initiated implementation consistently monitored year review internal auditing performed targeted routine audits well extraordinary audits around world addition adherence legal requirements internal group guidelines main focal points functionality systems effectiveness internal controls prevention loss assets efficiency structures processes corresponding adjust ments optimisations initiated necessary individual risks important risks boehringer ingelheim exposed broken follow ing specific categories financial risks legal risks production environmental risks personnel risks industryspecific risks risks identified concrete appear controllable means specific management procedures term abstract used case risks completely controlled even means targeted management procedures regardless probability occurrence financial risks relevant financial risks broken follows currency risks credit country specific risks well financial investment shareholding risks laicnanif detadilosnoc stnemetats boehringer ingelheim annual report currency risks global orientation business activities subject opportunities risks due exchange rate volatility particularly regard us dollar japanese yen group monitors quantifies risks regular intervals making predictable future business means rel evant hedging strategies appropriate financial instruments forward exchange contracts resultant risks subsequently designated concrete controllable therefore limited credit countryspecific risks boehringer ingelheim exposed various credit countryspecific risks result interna tional business activities portfolio trade accounts receivable trade accounts payable identified extraordinary risks group beyond usual level sector applies possible default risks receivables largely hedged economic political risks continue carefully track credit countryspecific risks position respond negative changes timely manner risks consider moderate fore regarded concrete financial investment shareholding risks group pursues defensive investment strategy management financial assets reflected orientation portfolio focused european economic monetary union emu government bonds top credit ratings shortterm investments selected banks results concrete controllable thus limited risk therefore limited opportunities major part financial investments net book value strategic investments related companies affected market business circumstances leads higher vola tility fair market value specific risks covered respective impairments con solidated financial statements legal risks business activities group exposed legal risks distinction made regula tory liability patent protection risks regulatory risks boehringer ingelheim exposed risks arising legal disputes proceedings well official investigations legal administrative decisions ongoing future proceedings predicted regard resultant risks abstract high liability risks marketing sale pharmaceuticals exposed potential product liability risk boehringer ingelheim currently product liability insurance companys risk profile absolutely guarantee however insurance coverage maintained reasonable cost accept able conditions sufficient protect boehringer ingelheim claim loss potential claims losses case foreseeable product liability insurance cover partially covers specific liability risk remaining risk exposure covered pro vision therefore see moderate risk group group management report furthermore product liability claims could tie substantial financial resources management capacity detrimental companys image event market considers product unsafe ineffective result unexpected side effects see moderate abstract risk patent protection risks protection innovations trademark brand patent rights particular importance boehringer ingelheim research company commercial protective rights increasingly target attacks breaches taken necessary precautions allow us detect threats early stage commencing appropriate countermeasures defend legal position using legal means available us moderate risks regarded concrete production environmental risks quality management system compliance processes continuously optimised close coop eration relevant authorities order ensure compliance cgmp standards current good manufacturing practices risks area continue high significance group classified abstract order guarantee supply products market implemented measures guarantee reliable highquality supplies internal external customers addition supplier management procurement side also involves building internal standby capacities result see risk concrete risks areas environment health safety sustainability ehss preemptively mini mised ensuring global adherence high safety standards appropriate emergency plans drawn possible incidents kind practised subjected comprehensive quality testing regular intervals result measures risks classed concrete limited personnel risks boehringer ingelheim companies exposed demographic change resultant risk affected lack appropriately qualified personnel potential risk substantial impact companys business activities therefore included longterm planning process many years gained strategic significance result boehringer ingelheim counters risk means comprehensive personnel concept con text global personnel management also presents group opportunities regardless ethnic background gender religion offer company employees development opportuni ties based vocational skills social expertise personal aptitudes willingness take responsibility accordance needs company view countermeasures described risk regarded moderate concrete industryspecific risks boehringer ingelheim exposed business risks specific pharmaceutical industry risks materialised past financial year increasing significance result impact boehringer ingelheim continue classed significant abstract laicnanif detadilosnoc stnemetats boehringer ingelheim annual report addition loss exclusivity products established market risks associated development registration new products industryspecific risks increasingly include changing restrictive requirements relating pricing reimbursement many sales markets frequently prices pharmaceutical products subject state monitoring regula tion also price pressure cheaper generic drugs caused state reimbursement sys tems boehringer ingelheim therefore keeping close eye various changes sales markets takes appropriate measures response current developments overall statement risk situation current perspective aware risks alone conjunction risks could lead lasting impairment companys net assets financial earnings position could jeopardise continued existence boehringer ingelheim report expected developments boehringer ingelheim look back successful financial year achieved ambitious targets absolute figures comparison competitors laid foundations sustainable development longterm growth demonstrated consistent focus business innovationoriented fields strategic exchange sanofis animal health business merial boehringer ingelheims consumer health care business transaction successfully closed january transaction improved competitiveness animal health business industrys important growth mar kets animal health business growing second year following integration merial busi ness successfully managed demanding task incorporating organisation many products new customers processes expect provide group growth momentum future sales growth increasingly difficult market environment increased unpredictability business poses expected major challenges entire pharmaceutical industry continue require significant atten tion boehringer ingelheim regard competitiveness even impor tant therefore retain scope growth innovation well financial ability act continue successful market future view many change pro cesses healthcare systems faced ageing populations increasing price pressure many major markets expect see low growth impetus pharmaceutical industry coming year comparable basis adjusted currency extraordinary effects expect see slight increase net sales boehringer ingelheim rd expenses remain continuously high line strategy drive growth promote new products future primarily products rd facilities invest area care close investigation therapeutic benefit associated prospects success replenishment innovative medicines research pipeline shows short mid longterm growth potential envisage slight increase investments rd new phar maceuticals group management report addition patent expiry attacks patents major challenges facing researchdriven pharmaceutical industry increasing amount investment rd well bigger hurdles increased costs associated product approvals context increasing cost pressure healthcare systems outlined must also particularly emphasised systems increas ingly unwilling substantially adequately reward high investments development new medicines value contribution increasing efficiency system whole result significant price pressure major markets prescription medicines conjunction longer planning development cycles new products makes business less predictable requires us recognise seize opportunities quickly one hand subjecting costs strategies continual monitoring adjustments hand end launched initiatives past years accelerate reaction changes reduce organisational complexities well lower cost base order create potential investments secure companys longterm success difficult market environment one hand potential resulting measures introduced well promising new product launches hand plan see operating income comparable basis adjusted currency extraordinary effects slightly last years level familyowned company boehringer ingelheims primary aim maintain groups indepen boehringer ingelheim dence competitiveness longterm sustainable organic growth still takes precedence well positioned shortterm profit targets confident achieve ambitious targets future businesses thanks great innovative strength based comprehensive portfolio prospective products global presence support highly qualified motivated employees stand vision value innovation develop bring market innovative prod ucts areas high unmet medical need therapeutic approaches aim first aim endeavours make new medicines available allow treatments humans animals effectively currently possible laicnanif detadilosnoc stnemetatspage c n l e f n n c l e e n overview selected consolidated companies consolidated balance sheet consolidated profit loss statement cash flow statement statement changes group equity notes consolidated financial statements independent auditors report laicnanif detadilosnoc stnemetats boehringer ingelheim annual report overview selected consolidated companies ch boehringer sohn ag co kg ingelheim rhein boehringer ingelheim vetmedica gmbh ingelheim rhein argentina mexico germany p r boehringer ingelheim animal health boehringer ingelheim animal health boehringer ingelheim corporate argentina sa buenos aires mxico sa de cv mexico city center gmbh ingelheim rhein australia r netherlands p boehringer ingelheim gmbh ingelheim rhein boehringer ingelheim animal health boehringer ingelheim animal health boehringer ingelheim pharma australia pty ltd netherlands bv alkmaar gmbh co kg ingelheim rhein north ryde boehringer ingelheim microparts new zealand p r gmbh dortmund belgium boehringer ingelheim animal health boehringer ingelheim venture fund boehringer ingelheim animal health new zealand ltd manukau city gmbh ingelheim rhein belgium sa brussels boehringer ingelheim puerto rico p biopharmaceuticals gmbh brazil p r ingelheim rhein boehringer ingelheim animal health boehringer ingelheim animal health puerto rico llc boehringer ingelheim veterinary brasil ltda paulo barceloneta research center gmbh co kg hanover canada south africa boehringer ingelheim middle east africa gmbh ingelheim rhein merial canada inc burlington boehringer ingelheim animal health south africa pty ltd randburg china p r south korea nanchang boehringer ingelheim animal health co ltd nanchang boehringer ingelheim animal health boehringer ingelheim animal health korea ltd seoul shanghai co ltd shanghai spain denmark p r boehringer ingelheim animal health boehringer ingelheim animal health espaa sa barcelona denmark copenhagen taiwan france p r boehringer ingelheim animal health merial sas lyon taiwan co ltd taipei great britain p thailand boehringer ingelheim animal health boehringer ingelheim animal health uk limited bracknell thailand limited bangkok italy p usa p r boehringer ingelheim animal health boehringer ingelheim animal health italia spa milan usa inc wilmington delaware japan r boehringer ingelheim animal health japan co ltd tokyo distribution p production r research development consolidated financial statements overview selected consolidated companies ch boehringer sohn grundstcksverwaltung gmbh co kg ingelheim rhein boehringer ingelheim international gmbh ingelheim rhein argentina p colombia italy p r south africa boehringer ingelheim sa boehringer ingelheim sa boehringer ingelheim italia spa ingelheim pharmaceuticals buenos aires santa f de bogot milan proprietary ltd randburg bidachem spa fornovo giovanni australia p czech republic south korea boehringer ingelheim pty ltd boehringer ingelheim spol sro japan p r boehringer ingelheim korea ltd north ryde prague nippon boehringer ingelheim co ltd seoul tokyo boehringer ingelheim vetmedica austria p r denmark boehringer ingelheim seiyaku korea ltd seoul yamagata boehringer ingelheim rcv gmbh boehringer ingelheim danmark co kg vienna copenhagen boehringer ingelheim japan inc spain p tokyo forschungsinstitut fr molekulare boehringer ingelheim espaa sa pathologie gesellschaft mbh vienna ecuador barcelona mexico p r boehringer ingelheim del ecuador belgium cia ltda quito boehringer ingelheim mexico sa de sweden cv mexico city scs boehringer ingelheim commv boehringer ingelheim aktiebolag brussels finland boehringer ingelheim vetmedica sa stockholm de cv guadalajara boehringer ingelheim finland ky brazil p espoo switzerland netherlands boehringer ingelheim brasl boehringer ingelheim schweiz qumica e farmaceutica ltda france boehringer ingelheim bv alkmaar gmbh basel paulo boehringer ingelheim france sas solana agro pecuria ltda arapongas paris new zealand taiwan boehringer ingelheim nz ltd boehringer ingelheim taiwan ltd canada great britain auckland taipei boehringer ingelheim canada ltd boehringer ingelheim ltd toronto bracknell norway thailand v boehringer ingelheim norway ks boehringer ingelheim thai limited chile greece p asker bangkok boehringer ingelheim ltda boehringer ingelheim ellas ae santiago de chile athens philippines turkey boehringer ingelheim philippines boehringer ingelheim ila ticaret china p r hong kong inc manila istanbul boehringer ingelheim shanghai boehringer ingelheim hong kong pharmaceuticals co ltd shanghai ltd hong kong poland usa p r boehringer ingelheim boehringer ingelheim sp z oo boehringer ingelheim biopharmaceuticals china co ltd india warsaw pharmaceuticals inc shanghai wilmington delaware b ino eh sr ti mng ee nr cn og e l lh te dim china b lto de h mrin ug br igelheim india private portugal boehringer ingelheim fremont inc wilmington delaware shanghai unilfarmauniao internacional de boehringer ingelheim international indonesia p laboratrios farmacuticos lda boehringer ingelheim usa trading shanghai co ltd lisbon corporation wilmington delaware pt boehringer ingelheim indonesia shanghai boehringer ingelheim vetmedica jakarta russian federation vietnam china co ltd taizhou israel ooo boehringer ingelheim moscow boehringer ingelheim animal health vietnam limited liability company boehringer ingelheim israel ltd ho chi minh city tel aviv oiloftrop tcudorp boehringer ingelheim annual report consolidated balance sheet assets eur million notes intangible assets tangible assets financial assets fixed assets inventories accounts receivable assets cash cash equivalents current assets prepaid expenses deferred tax assets exceeding amount plan assets total assets equity liabilities eur million notes shareholders capital group reserves balance sheet currency conversion difference equity attributable parent company noncontrolling interests group equity difference capital consolidation provisions accounts payable loans liabilities deferred income deferred tax liabilities total equity liabilities explanations see relevant section notes consolidated financial statements consolidated financial statements consolidated balance sheet consolidated profit loss statement consolidated profit loss statement eur million notes net sales changes finished goods work process work capitalised operating income total revenues cost materials personnel expenses amortisation intangible assets depreciation tangible assets operating expenses operating income financial income holding income income taxes income taxes income taxes net incomeloss noncontrolling interests group profitloss explanations see relevant section notes consolidated financial statements due legal requirements shareholders personal taxes arising group business activities shown withdrawals group reserves oiloftrop tcudorp boehringer ingelheim annual report cash flow statement eur million income taxes including noncontrolling interests amortisation reversal writedowns intangible assets depreciation reversal writedowns tangible assets change provisions pensions similar obligations without acquiring generating plan assets change provisions noncash income expenses gain disposals consolidated companies gainloss disposals fixed assets grants received change inventories change accounts receivable assets related investing financing activities change trade accounts payable liabilities related investing financing activities interest incomeinterest expenses income investments incomeexpenses extraordinary magnitude significance income taxes income taxes paid cash flow operating activities payments acquire intangible fixed assets payments acquire tangible fixed assets payments acquire financial fixed assets payments acquire generate plan assets investments consolidated companies proceeds disposals intangible fixed assets proceeds disposals tangible fixed assets proceeds disposals financial fixed assets cash receipts relating purchase price adjustment consolidated companies cash receipts extraordinary magnitude significance interest received income dividends cash flow investing activities consolidated financial statements cash flow statement statement changes group equity cash flow statement eur million cash receipts grants interest paid cash payments shareholders parent company cash payments shareholders parent company proceeds loans cash repayments loans cash flow financing activities change financial funds cash relevant transactions changes financial funds due change consolidated companies changes financial funds due exchange rate movements financial funds financial funds excl investment securities cash cash equivalents investment securities within fixed assets source funds use funds statement changes group equity balance sheet equity attri currency butable non shareholders group conversion parent controlling eur million capital reserves difference company interests group equity balance withdrawals net loss changes consolidated companies currency effects balance contributions withdrawals net income changes consolidated companies currency effects balance shareholders capital consists equity ch boehringer sohn ag co kg ch boehringer sohn grundstcksverwaltung gmbh co kg shareholders capital consists limited partners capital contribution shareholders personal taxes arising group business activities shown withdrawals group reserves oiloftrop tcudorp boehringer ingelheim annual report notes consolidated financial statements principles methods general principles consolidated financial statements boehringer ingelheim financial year prepared accord ance section german commercial code hgb line legal requirements prepare consolidated financial statements section et seq hgb accordance section hgb consolidated financial statements consist consolidated balance sheet consolidated profit loss statement notes consolidated financial statements cash flow statement statement changes equity consolidated financial statements prepared euros accordance section conjunction section hgb improve clarity transparency consolidated financial statements individual items consoli dated balance sheet consolidated profit loss statement combined items presented explained separately notes additional disclosures required individual items also found notes registry information parent company registered name ch boehringer sohn ag co kg headquarters ingelheim rhein commercial register mainz district court number hra information group consolidated companies parent company boehringer ingelheim group ch boehringer sohn ag co kg ingelheim rhein boehringer ag ingelheim rhein sole personally liable managing shareholder company besides ch boehringer sohn ag co kg ch boehringer sohn grundstcksverwaltung gmbh co kg ingelheim rhein whose general partner controlled ch boehringer sohn ag co kg boehringer ingelheim group consists total affiliated companies germany abroad consol idated financial statements ch boehringer sohn ag co kg include fully consolidated subsidiaries ch boehringer sohn grundstcksverwaltung gmbh co kg consolidated special purpose entity majority risks rewards business activities attributable ch boehringer sohn ag co kg remaining subsidiaries ch boehringer sohn ag co kg directly indirectly holds majority voting rights accordance section hgb affiliated companies included consolidation reporting year individually collectively insignificant groups net assets financial earnings position total amount sales equity net income year affiliated companies included consolidation accounts less aggregated group financial statements totals two affiliated companies ongoing restrictions control due terms articles association companies also consolidated accordance section hgb consolidated financial statements notes total number affiliated companies decreased five compared previous year one new company founded one company acquired six companies lost separate legal identity merger one affiliated company liquidated viratherapeutics gmbh innsbruck acquired september following subsidiaries exempt duty prepare disclose annual financial statements management reports accordance section hgb boehringer ingelheim gmbh ingelheim rhein boehringer ingelheim europe gmbh ingelheim rhein boehringer ingelheim secura versicherungsvermittlungs gmbh ingelheim rhein boehringer ingelheim grundstcksgesellschaft mbh ingelheim rhein boehringer ingelheim finanzierungs gmbh ingelheim rhein boehringer ingelheim rd beteiligungs gmbh ingelheim rhein boehringer ingelheim venture fund gmbh ingelheim rhein boehringer ingelheim invest gmbh ingelheim rhein following subsidiaries exempt duty prepare disclose annual financial statements management reports accordance section b hgb ch boehringer sohn ag co kg ingelheim rhein ch boehringer sohn grundstcksverwaltung gmbh co kg ingelheim rhein boehringer ingelheim pharma gmbh co kg ingelheim rhein boehringer ingelheim veterinary research center gmbh co kg hanover two joint ventures included cost instead either using proportionate method equity method due lack significance accordance section hgb associated companies valuated using equity method due lack significance oiloftrop tcudorp boehringer ingelheim annual report consolidation methods inventories fixed assets receivables liabilities income expense items transactions companies included consolidation eliminated part debt consolidation procedures accordance section hgb procedures eliminate intercompany profits accordance section hgb income expenses consolidation procedures accordance section hgb acquisition method applied including subsidiaries consolidation first time accordance section hgb companies included consolidation first time date company became subsidiary book value shares held parent company offset corresponding equity subsid iary equity carried amount fair value assets liabilities prepaid expenses deferred income special reserves included consolidated financial statements time consolidation remaining positive balance recorded goodwill remaining negative balance recorded difference capital consolidation currency translation assets liabilities resulting foreign currency transactions translated using average spot exchange rate balance sheet date realisation principle section conjunction section halfsentence hgb historical cost convention section conjunction section sentence hgb applied items remaining term one year consolidated financial statements financial statements foreign subsidiaries domiciled state outside eurozone denominated foreign currency converted euros accordance section hgb using modified closing date rate method using modified closing date rate method asset liability items annual financial statements pre pared foreign currency translated euros using average spot exchange rate balance sheet date exception equity translated using historical rate items included profit loss statement translated euros using average rate resulting translation difference reported within consolidated equity reserves balance sheet currency conversion difference exchange rates groups important currencies changed follows reporting year basis eur closing rate average annual rate us dollar japanese yen chinese renminbi pound sterling consolidated financial statements notes accounting policies fixed assets acquired intangible assets tangible fixed assets carried cost less scheduled straightline amortisation depreciation considering technical economic circumstances based following useful lives intangible assets years buildings years technical equipment machinery years equipment operating office equipment years straightline depreciation amortisation used consolidated financial statements additional writedowns recorded reflect impairments value assets considered permanently impaired manufacturing costs include materials labour manufacturing costs appropriate portion mate rials labour overheads depreciation fixed assets extent caused production manufacturing costs include financing costs capitalised intangible assets finite useful lives useful life ten years applied goodwill viratherapeutics gmbh acquired year past experi ence products sales markets together business conditions viratherapeutics gmbh indicates presents true fair view financial assets primarily include investment securities shareholder rights loans carried lower cost fair market value impaired reasons impairment made previous financial years longer existed appropriate writeups made current assets prepaid expenses deferred charges exceeding amount plan assets inventories carried lower cost fair market value raw materials consumables supplies capitalised lower average acquisition prices fair market value balance sheet date finished goods work progress measured manufacturing cost basis individual calculations taking account directly attributable costs materials direct labour costs special direct costs appropriate portion material production overhead costs productionrelated depreciation goods resale valued lower either acquisition cost fair market value oiloftrop tcudorp boehringer ingelheim annual report identifiable risks inventories arising aboveaverage storage periods diminished marketability lower replacement costs taken account recording appropriate valuation adjustments inventories valued lossfree e deductions made expected sales prices reflect costs yet incurred receivables assets recognised cost less allowances specific risks general credit risk lowinterest noninterestbearing receivables term one year discounted cash cash equivalents consisting cash balances banks cheques recognised lower cost fair market value prepaid expenses recorded accordance section hgb include expenses paid advance respect defined period time balance sheet date deferred income recorded accordance section hgb include proceeds represent income relating defined period time balance sheet date fair market value plan assets corresponding present value pension obligation offset according german gaap exceeding amount plan assets capitalised separately difference capital consolidation difference capital consolidation reported december primarily result business swap boehringer ingelheims consumer health care business sanofis animal health business completed january resulted difference capital consolidation eur million difference amortised estimated period years remaining balance difference amounted eur million december difference capital consolidation reported december also included amount arising acquisition us company original difference amounted eur million difference amor tised estimated period ten years remaining balance difference amounted eur million december income release difference arising capital consolidation included operating income release made corresponding amortisation assets acquired company identified purchase price allocation previously recognised companys balance sheet consolidated financial statements notes group reserves group reserves include retained earnings consolidated subsidiaries prior current years consolidation entries affect earnings provisions tax provisions provisions include uncertain liabilities expected losses executory contracts carried amount required settle obligation based reasonable prudent commercial judgement e including future cost price increases provisions remaining maturity one year discounted using matchedterm average market interest rate case pension provisions interest rate results last ten years average case provisions last seven years average accordance rckstellungsabzinsungsverordnung german regulation discounting provisions accounts payable loans accounts payable loans recognised settlement amount deferred taxes calculate deferred taxes arising temporary quasipermanent differences carrying amounts assets liabilities prepaid expenses deferred income group financial statements carrying amounts tax purposes tax loss carryforwards amounts resulting tax benefits expenses time differences reverse measured using tax rates specific respective consolidated company deferred tax balances discounted differences due consolidation measures accordance sections hgb also measured using company specific tax rates applicable time expected reversal difference deferred tax assets loss carryforwards taken account likely used within next five years deferred tax assets liabilities reported without offsetting oiloftrop tcudorp boehringer ingelheim annual report notes consolidated balance sheet intangible assets acquired concessions advance eur million similar rights goodwill payments total acquisitionmanufacturing costs balance january currency conversion difference changes consolidated companies additions disposals reclassifications balance december currency conversion difference changes consolidated companies additions disposals reclassifications balance december accumulated amortisation balance january currency conversion difference changes consolidated companies additions writeups disposals reclassifications balance december currency conversion difference changes consolidated companies additions writeups disposals reclassifications balance december book value december book value december consolidated financial statements notes tangible assets advance technical facilities payments land facilities operating construction eur million buildings machines equipment progress total acquisitionmanufacturing costs balance january currency conversion difference changes consolidated companies additions disposals reclassifications balance december currency conversion difference changes consolidated companies additions disposals reclassifications balance december accumulated depreciation balance january currency conversion difference changes consolidated companies additions writeups disposals reclassifications balance december currency conversion difference changes consolidated companies additions writeups disposals reclassifications balance december book value december book value december oiloftrop tcudorp boehringer ingelheim annual report financial assets investments loans investments affiliated affiliated related advance investment eur million companies companies companies payments securities loans total acquisitionmanufacturing costs balance january currency conversion difference changes consolidated companies additions disposals reclassifications balance december currency conversion difference changes consolidated companies additions disposals reclassifications balance december accumulated amortisation balance january currency conversion difference changes consolidated companies additions writeups disposals reclassifications balance december currency conversion difference changes consolidated companies additions writeups disposals reclassifications balance december book value december book value december previous year loans item include loans shareholders consolidated financial statements notes inventories eur million raw materials supplies unfinished goods finished goods goods resale advance payments suppliers accounts receivable assets residual term residual term eur million year year trade accounts receivable receivables affiliated companies receivables related companies assets assets item included receivables shareholders around half million euro previous year eur million receivables affiliated companies almost exclusively consisted receivables loans receivables related companies primarily consisted trade accounts receivable provisions eur million pension provisions similar obligations tax provisions provisions oiloftrop tcudorp boehringer ingelheim annual report provisions pensions similar obligations provisions pensions similar obligations determined basis actuarial calculations using projected unit credit method taking account future adjustments salaries pensions addition local biometric data eg germany mortality tables g published prof dr klaus heubeck adjusted groupspecific death probabilities invalidity rates pension obligations significant countries calculated basis following actuarial parameters december germany usa japan discount rate salary increase pension increase discounting rates determined reference average market rates year maturities accordance german regulation discounting provisions march interest rates used discount significant foreign pension obligations usa japan determined comparable parameters line german regulation discounting provisions march difference calculated accordance section hgb amounts eur million plan assets intended solely cover pension similar obligations unavailable creditors plan assets defined section sentence hgb measured fair market value essentially derived stock market prices offset underlying pension similar obligations fair market value plan assets balance sheet date eur million related amount pension obligations similar obligations eur million gains losses plan assets interest expense relating pension similar obligations offset accordance section sentence hgb total eur mil lion losses plan assets eur million interest expense relating pension similar obligations included interest expense relating pensions similar obligations provisions within financial result tax provisions tax provisions also include provisions double taxation risks resulted following implementation action plans organisation economic cooperation development oecd part international initiative known action plan base erosion profit shifting beps consolidated financial statements notes provisions provisions mainly include provisions discounts guarantees personnelrelated provisions provisions outstanding invoices well provisions litigation legal claims compensation damages accounts payable loans residual term residual term less greater greater less eur million year year years year bank loans accounts payable trade accounts payable advance payments received accounts payable affiliated companies accounts payable related companies liabilities taxes eur million social security liabilities eur million previous year liabilities secured mortgages similar collateral rights balance sheet date end year liabilities shareholders eur million previous year eur million presented within liabilities item accounts payable affiliated companies include loans amounting eur million previous year eur million trade accounts payable amounting eur million previous year eur million oiloftrop tcudorp boehringer ingelheim annual report notes consolidated profit loss statement structure consolidated profit loss statement based total cost format taxes included operating expenses net sales businesses eur million human pharmaceuticals animal health biopharmaceuticals sales dicontinued operations geographic region eur million europe germany americas usa asiaaustraliaafrica japan operating income operating income includes income currency translation eur million previous year eur million cost materials eur million costs raw material supplies goods resale expenditure services consolidated financial statements notes personnel expenses eur million wages salaries social benefits retirement benefits retirement benefits interest effects measurement provisions pensions similar obligations shown separate item financial income average headcount production administration marketing sales research development apprentices allocation employees among different functions restated many former merial employees allocated respective function first year merial consolidated rather reported within administration amortisation intangible assets depreciation tangible assets amortisation intangible assets depreciation tangible fixed assets include extraordinary writedowns eur million previous year eur million operating expenses operating expenses include expenses currency translation eur million previous year eur million addition items included operating expenses mainly charges made record provisions legal risks restructuring well thirdparty services research development medicine marketing purposes administrative expenses fees contributions commissions rent freight expenses repairs carried third parties oiloftrop tcudorp boehringer ingelheim annual report financial income eur million interest expense relating pensions similar obligations provisions interest expense similar expenditure interest expense similar expenditure amortisation loss disposal financial fixed assets shortterm invest ments income investment securities longterm loans interest income similar income holding income eur million writedowns financial fixed assets writeups financial fixed assets income related companies disposal related companies income taxes eur million current income taxes deferred taxes current income taxes primarily include corporation trade tax expenses consolidated companies total balance deferred tax assets balance sheet date amounted eur million previous year eur million deferred tax assets primarily arise difference book values provisions pension obligations discounts tax goodwill intangible fixed assets inventories tangible fixed assets deferred tax liabilities eur million previous year eur million recorded primarily relate differences book values intangible fixed assets tangible fixed assets inventories provisions consolidated financial statements notes net income net income positively influenced priorperiod operating income mainly reversal provisions tax refunds prior years eur million previous year eur million negatively influenced priorperiod operating expenses mainly due additional payment taxes prior years eur million previous year eur million notes cash flow statement cash flow statement shows changes cash cash equivalents cash longterm investment securities sold time boehringer ingelheim group resulting cash inflows outflows reporting year accordance german accounting standard cash flow statement drs cash flow statement broken according cash flows operating activities cash flows investing financing activities changes balance sheet items affiliated companies included translated using average rates year balance sheet cash cash equivalents carried closing rate effect exchange rate changes cash cash equivalents shown separately financial funds also include financial assets remaining maturity exceeding three months date acquisition converted cash short term financial funds december comprised following items eur million cash cash equivalents financial assets financial funds included eur million restricted funds balance sheet date oiloftrop tcudorp boehringer ingelheim annual report disclosures contingent liabilities eur million liabilities guarantees warranties granting securities thirdparty liabilities risk utilisation contingent liabilities assessed low account good net assets financial earnings position financial commitments offbalance sheet transactions eur million rental lease obligations residual financial commitments pensionrelated rental lease obligations eur million previous year eur million eur million previous year eur million relate longterm rental obligations nonconsolidated affiliated companies purpose lease agreements lower capital commitment compared acquired property absence resale risk risks could arise term lease possible continue utilise properties fully indications time residual financial commitments include future expenditureeffective investments eur million previous year eur million derivative financial instruments valuation units due extensive international structure boehringer ingelheim group highly dependent developments worlds currencies interest rates hedge risks particularly emerging goods services financing currency forwards options generally used currency risks interest rate swaps options used interest rate risks use derivative financial instruments organisational processes set internal guidelines strict separation trading processing documentation control consolidated financial statements notes risk positions regularly tracked analysed measured special groupwide financial report positions entered periodically reevaluated monitored fair value derivative financial instruments cal culated using generally accepted market valuation methods currency forwards based present value method taking account market data balance sheet date provisions eur million recognised currency forwards included hedge accounting negative fair value within one currency balance sheet date line imparity principle positive fair values within one currency recognised balance sheet date derivative financial instruments included hedge accounting valuation units follows nominal value fair value eur million foreign exchange forward contracts extent requirements hedge accounting foreign currency forward exchange contracts highly probable forecasted transactions accordance section hgb met foreign currency forward exchange contracts recognised balance sheet line net hedge presentation method following accounting policies apply recognition valuation groups accordance section hgb economic hedges accounted financial statements use valuation units valuation units recognised foreign currency based net amount highly probable forecasted transactions cur rency forwards match forecasted net cash flow terms maturity nominal amount foreign currency macro hedge highly probable forecasted transactions incoming outgoing payments planned sales purchases derived company planning expost analysis planning shown planned transac tions highly probable opposing changes value hedged item hedging instrument fully offset critical terms maturity nominal amount foreign currency match effective hedge therefore assumed prospectively retrospectively critical term match method exclusively used measure prospective retrospective effectiveness hedges excess amounts hedging transactions included valuation units oiloftrop tcudorp boehringer ingelheim annual report december hedges highly probable forecasted net cash flows recognised follows january december net cash flow eur million foreign exchange forward contracts eur million nominal value nominal value fair value usd usd usd jpy jpy jpy aud aud aud mxn mxn mxn cad cad cad gbp gbp gbp january december net cash flow eur million foreign exchange forward contracts eur million nominal value nominal value fair value usd usd usd jpy jpy jpy aud aud aud mxn mxn mxn cad cad cad gbp gbp gbp january december net cash flow eur million foreign exchange forward contracts eur million nominal value nominal value fair value usd usd usd jpy jpy jpy consolidated financial statements notes january february net cash flow eur million foreign exchange forward contracts eur million nominal value nominal value fair value usd usd usd jpy jpy jpy year also hedge accounting valuation units long short positions derivatives offsetting nominal values amount eur million japanese yen furthermore december valuation units foreign currency receivables recognised follows receivables eur million foreign exchange forward contracts eur million nominal value nominal value fair value rub rub rub pln pln pln amount hedged foreign currency risk correlates relative change exchange rate planning date realisation date forecast transactions currencies appreciate depreciate euro would foreign currency risk plus minus eur million without hedging research development expenses eur million research development expenses noncapitalised research development expenses include amongst items costs associated clinical studies shareholdings list companies included consolidated financial statements list shareholdings presented accordance section hgb included audited consolidated financial statements submitted german federal gazette subsequent events since end financial year become aware events material significance group could lead reappraisal net assets financial earnings position oiloftrop tcudorp boehringer ingelheim annual report total auditor fees total fees charged group auditor financial year amounted eur million eur million relates audits financial statements eur million tax advisory services eur million services ingelheim rhein march boehringer ag board managing directors hubertus von baumbach joachim hasenmaier allan hillgrove dr andreas neumann dr michel pairet michael schmelmer independent auditors report independent auditors report ch boehringer sohn ag co kg ingelheim rhein qualified audit opinion consolidated financial statements audit opinion group manage ment report audited consolidated financial statements ch boehringer sohn ag co kg ingelheim rhein subsidiaries group comprise consolidated balance sheet december consolidated profit loss statement cash flow statement statement changes group equity financial year january december notes consolidated financial statements including summary significant accounting policies addition audited group management report ch boehringer sohn ag co kg financial year january december opinion basis knowledge obtained audit except effects matter described section basis qualified audit opinion consoli dated financial statements audit opinion group management report accompanying consol idated financial statements comply material respects requirements german commercial law give true fair view assets liabilities financial position group december financial performance financial year january december accordance german legally required accounting principles accompanying group management report whole provides appropriate view groups position material respects group management report consistent consolidated financial statements complies german legal requirements appropriately presents opportunities risks future development pursuant section sentence hgb handelsgesetzbuch german commercial code declare except qualification audit opinion consolidated financial statements mentioned audit led reservations relating legal compliance consolidated financial statements group management report basis qualified opinion consolidated financial statements audit opinion group management report contrary section number letters b hgb total remuneration granted members former members board managing directors well pension provisions recognized recognized former members board managing directors disclosed notes consol idated financial statements conducted audit consolidated financial statements group management report accord ance section hgb german generally accepted standards financial statement audits promul gated institut der wirtschaftsprfer institute public auditors germany idw responsibilities requirements principles described auditors responsibilities audit consolidated financial statements group management report section auditors report independent group entities accordance requirements german commercial professional law oiloftrop tcudorp boehringer ingelheim annual report fulfilled german professional responsibilities accordance requirements believe evidence obtained sufficient appropriate provide basis opinions consolidated financial statements group management report information management responsible information information comprises annual report exception audited consolidated financial statements group management report auditors report opinions consolidated financial statements group management report cover information consequently express opinion form assurance conclusion thereon connection audit responsibility read information consider whether information materially inconsistent consolidated financial statements group management report knowledge obtained audit otherwise appears materially misstated responsibilities management consolidated financial statements group management report management responsible preparation consolidated financial statements comply material respects requirements german commercial law consolidated financial statements give true fair view assets liabilities financial position financial performance group compliance german legally required accounting principles addition management responsible internal control accordance german legally required accounting principles determined necessary enable preparation consolidated financial statements free material misstatement whether due fraud error preparing consolidated financial statements management responsible assessing groups ability continue going concern also responsibility disclosing applicable matters related going concern addition responsible financial reporting based going concern basis accounting provided actual legal circumstances conflict therewith furthermore management responsible preparation group management report whole provides appropriate view groups position material respects consistent consoli dated financial statements complies german legal requirements appropriately presents opportunities risks future development addition management responsible arrangements measures systems considered necessary enable preparation group management report accordance applicable german legal requirements able provide sufficient appropriate evidence assertions group management report independent auditors report auditors responsibilities audit consolidated financial statements group manage ment report objectives obtain reasonable assurance whether consolidated financial statements whole free material misstatement whether due fraud error whether group management report whole provides appropriate view groups position material respects consistent consolidated financial statements knowledge obtained audit complies german legal require ments appropriately presents opportunities risks future development well issue auditors report includes opinions consolidated financial statements group management report reasonable assurance high level assurance guarantee audit conducted accordance section hgb compliance german generally accepted standards financial statement audits promulgated institut der wirtschaftsprfer idw always detect material misstatement misstatements arise fraud error considered material individually aggregate could reasonably expected influence economic decisions users taken basis consoli dated financial statements group management report exercise professional judgement maintain professional scepticism throughout audit also identify assess risks material misstatement consolidated financial statements group management report whether due fraud error design perform audit procedures responsive risks obtain audit evidence sufficient appropriate provide basis opinions risk detecting material misstatement resulting fraud higher one resulting error fraud may involve collusion forgery intentional omissions misrepresentations override internal controls obtain understanding internal control relevant audit consolidated financial statements arrangements measures systems relevant audit group management report order design audit procedures appropriate circumstances purpose expressing opinion effectiveness systems evaluate appropriateness accounting policies used management reasonableness estimates made management related disclosures conclude appropriateness managements use going concern basis accounting based audit evidence obtained whether material uncertainty exists related events conditions may cast significant doubt groups ability continue going concern conclude material uncertainty exists required draw attention auditors report related disclosures consolidated financial statements group management report disclosures inadequate modify respective opinions conclusions based audit evidence obtained date auditors report however future events conditions may cause group cease able continue going concern evaluate overall presentation structure content consolidated financial statements including disclosures whether consolidated financial statements present underlying transactions events manner consolidated financial statements give true fair view assets liabilities financial position financial performance group compliance german legally required accounting principles oiloftrop tcudorp boehringer ingelheim annual report obtain sufficient appropriate audit evidence regarding financial information entities business activities within group express opinions consolidated financial statements group management report responsible direction supervision performance group audit remain solely responsible opinions evaluate consistency group management report consolidated financial statements conformity german law view groups position provides perform audit procedures prospective information presented management group management report basis sufficient appropriate audit evidence evaluate particular significant assump tions used management basis prospective information evaluate proper derivation prospective information assumptions express separate opinion prospective infor mation assumptions used basis substantial unavoidable risk future events differ materially prospective information communicate charged governance regarding among matters planned scope timing audit significant audit findings including significant deficiencies internal control identify audit frankfurt main march kpmg ag wirtschaftsprfungsgesellschaft original german version signed kneisel krau wirtschaftsprfer wirtschaftsprfer german public auditor german public auditorpages p r u c p r f l e l e c n human pharmaceuticals animal health oiloftrop tcudorp boehringer ingelheim annual report respiratory diseases respiratory diseases common chronic obstructive bronchial asthma pulmonary disease copd bronchial asthma among bronchial asthma chronic inflammatory disorder air prevalent chronic diseases frequent cause ways inflammation accompanied airway hyperre morbidity premature deaths worldwide sponsiveness leads narrowing airways recurrent episodes wheezing breathlessness coughing idiopathic pulmonary fibrosis ipf rare disease symptoms occur particularly night early severely debilitating ultimately lethal hours morning known asthma trig gered genetic environmental factors eg allergens copd viral infections unlike copd asthma occur early copd chronic disease lungs causes coughing childhood also present adolescents adults excessive mucus production dyspnea ultimately asthma often underestimated easytomanage condi destroys lung tissue alveoli thus gas exchange tion however almost one two patients asthma still affected leads limitation airflow experience symptoms receiving maintenance therapy causing shortness breath respiratory symptoms putting increased risk potentially lifethreatening airflow limitation partially reversible usually asthma exacerbations addition patients often adjust worsens time leading disability ultimately death daily lives accommodate conditions avoid physical symptoms excess cough breathlessness exertion daytoday activities negative impact main reasons copd stressful patients lung quality life emphysema chronic bronchitis main manifesta tions copd copd caused continuous damage lungs resulting inhaling pollutants primarily cigarette smoke however factors also need considered including indoor outdoor air pollution course copd disease occurs second half humans life character ised accelerated loss lung function compared mal ageing occasional sudden worsening symptoms function referred acute exacerbations lead downward spiral worsening symptoms thus inactivity product portfolio human pharmaceuticals indications brand names active ingredients chronic obstructive spiriva tiotropium bromide maintenance treatment patients pulmonary disease copd spiriva handihaler copd including chronic bronchitis spiriva respimat emphysema maintenance treatment associated dyspnoea prevention exacerbations bronchial asthma spiriva respimat tiotropium bromide addon maintenance bronchodilator treatment patients aged six years older severe asthma experienced one severe asthma exacerbations past year spiriva respimat approved use asthma eu japan usa many countries label varies country please refer local product information chronic obstructive spiolto respimat tiotropium bromide maintenance treatment airflow obstruc pulmonary disease copd stiolto respimat olodaterol tion patients chronic obstructive inspiolto respimat hydrochloride pulmonary disease copd chronic obstructive striverdi respimat olodaterol hydrochloride maintenance treatment patients pulmonary disease copd chronic obstructive pulmonary disease copd reversible bronchospasms combivent respimat ipratropium bromide combination shortacting anticholin associated obstructive salbutamol sulphate ergic betaadrenergic manage airway diseases ment reversible bronchospasms associ ated obstructive airway diseases patients requiring one bronchodi lator chronic obstructive atrovent ipratropium bromide prevention treatment shortness pulmonary disease copd breath patients chronic obstructive chronic bronchitis pulmonary disease copd mild mod bronchial asthma erate bronchial asthma adulthood childhood supplement betaagonists cases acute asthma chronic obstructive airway berodual ipratropium bromide fenoterol prevention treatment symptoms disorders bronchodual hydrobromide chronic obstructive airway disorders duovent reversible airflow limitation bron chial asthma especially chronic bronchi tis without emphysema boehringer ingelheim annual report respiratory diseases continued idiopathic pulmonary fibrosis ipf acute ipf exacerbations defined rapid deteriorations ipf chronic progressive lung disease associated symptoms lung function within days weeks markedly reduced life span affecting many events occur point course disease even people per worldwide ipf characterised progres first presentation associated high mortality sive scarring lung tissue loss lung function patients ipf risk acute ipf exacerbations time development scarred tissue called fibrosis time tissue thickens stiffens scarring lungs lose ability take transfer oxygen blood stream vital organs get enough oxygen result individuals ipf experience shortness breath even resting often difficulty coping demands everyday life due limited physical capacity product portfolio human pharmaceuticals indications brand names active ingredients bronchial asthma berotec fenoterol hydrobromide symptomatic treatment acute asthma attacks prophylaxis exerciseinduced asthma bronchiale symptomatic treatment allergic non allergic asthma bronchiale condi tions reversible airway narrowing eg chronic obstructive bronchitis bronchial asthma alesion epinastine hydrochloride prophylactic treatment patients allergic rhinitis flurinol bronchial asthma prophylaxis sympto matic treatment allergic rhinitis idiopathic pulmonary fibrosis ofev nintedanib treatment patients idiopathic ipf pulmonary fibrosis ipf boehringer ingelheim annual report cardiovascular metabolic diseases cardiovascular cv disease leading cause death prevention treatment venous worldwide still increasing prevalence currently thromboembolism responsible nearly one three deaths worldwide one key venous thromboembolism vte umbrella term risk factor developing cardiovascular disease presence encompasses deep vein thrombosis dvt pulmonary diabetes people type diabetes two four times embolism pe dvt occurs thrombus blood clot forms likely develop cardiovascular disease people deep vein commonly leg partially com without diabetes result life expectancy pletely blocks flow blood thrombus grows years shorter proper control diabetes treata portion may break away main clot travel ble risk factors therefore vital prevention cardio circulatory system lungs lodging blood clot vascular events arteries lung called pe vte serious disorder potentially fatal consequences stroke stroke rapidly developing loss brain functions caused patients undergoing orthopaedic surgery considerable disrupted blood flow affected brain tissue risk developing dvt chronic venous insufficiency due ischaemia lack blood supply caused thrombosis pulmonary hypertension may develop longer term embolism due bleeding hemorrhagic stroke prevent vte events consequences orthopaedic result affected area brain unable function surgery patients receive kind thromboprophy damage quickly becomes permanent untreated stroke laxis patients already suffered vte require anti acute event requiring emergency diagnosis interven coagulant treatment secondary prevention recurrent tion worldwide stroke one leading causes death thromboembolic event longterm disability reversing anticoagulation symptoms transient ischaemic attack tia similar anticoagulation therapy offers important benefits patients stroke last minutes hours risk thromboembolic events however even though rare result permanent neurological damage tia may precede may situations rapid reversal anticoagulation stroke emergency medical care subsequent preventive medically necessary eg patient taking anticoagulant treatment may necessary involved severe car accident needs emergency surgery atrial fibrillation atrial fibrillation af common sustained heart rhythm condition affecting approximately total pop ulation one four adults develops af lifetime patients af higher risk developing blood clots upper left heart chamber cause stroke clot breaks loose travels brain af leads fivefold increase risk stroke resulting three million patients worldwide suffering afrelated strokes year patients af risk stroke reduced appropri ate anticoagulation therapy product portfolio human pharmaceuticals indications brand names active ingredients stroke prevention atrial pradaxa dabigatran etexilate prevention strokes blood clots fibrillation pradaxar patients atrial fibrillation primary prevention venous prazaxa primary prevention venous thrombo thromboembolic events embolic events vte adults elective orthopaedic surgery total hip knee replacement surgery treatment secondary prevention venous throm treatment deep vein thrombosis dvt boembolic events pulmonary embolism pe secondary prevention recurrent dvt pe adults specific reversal pradaxa praxbind idarucizumab praxbind specific reversal agent dabigatran etexilate dabigatran indicated adult patients treated pradaxa dabigatran etexilate rapid reversal anticoagulant effects required emergency surgery urgent procedures lifethreatening uncontrolled bleeding hypertension micardis telmisartan treatment hypertension reduction cardiovascular morbidity risk myocardial infarction heart mortality prevention attack stroke death cardiovascular cv causes patients years age older high risk developing major cv events unable take ace inhibitors usa reduction cardiovascular morbidity patients manifest atherothrombotic cardio vascular disease history coronary heart disease stroke peripheral arterial disease patients type diabetes mellitus documented target organ damage eu hypertension micardisplus telmisartan treatment hypertension alone micardis plus hydrochlorothiazide antihypertensive agents lower micardis hct blood pressure lowering blood pressure reduces risk fatal nonfatal cardio comicardis vascular events primarily strokes myo cardial infarctions indicated initial therapy us treatment essential hypertension micardisp lus fixed dose combination indicated adults whose blood pressure adequately controlled telmisartan alone eu h ypertension twynsta telmisartan amlodipine treatment hypertension alone micamlo antihypertensive agents initial micardis amlo therapy patients likely need multiple antihypertensive agents achieve micardis duo blood pressure goals usa addon therapy adult patients adequately controlled blood pressure amlodipine replacement therapy adult patients receiving telmisartan amlodipine separate tablets eu boehringer ingelheim annual report cardiovascular metabolic diseases continued hypertension cardiovascular diseases hypertension high blood pressure chronic disease blood pressure chronically elevated hypertension also one major risk factors stroke heart attacks heart failure chronic renal failure primary goal anti hypertensive treatment prevent cardiovascular events reduce risk cardiovascular mortality acute myocardial infarction acute myocardial infarction heart attack occurs thrombus blood clot suddenly prevents blood flow area heart muscle unless blood flow restored quickly affected section heart muscle becomes permanently damaged heart attacks one common causes death industrialised countries product portfolio human pharmaceuticals indications brand names active ingredients acute ischaemic stroke actilyse alteplase fibrinolytic treatment acute ischaemic acute myocardial infarction actilyse cathflo stroke acute myocardial infarction acute acute massive pulmonary massive pulmonary embolism fibrinolytic embolism treatment occluded catheters catheter clearance due thrombotic occlusion secondary prevention aggrenox dipyridamole prevention stroke following initial first stroke transient ischaemic asasantin acetylsalicylic acid stroke transient ischaemic attacks tia attacks tia asasantin retard acute myocardial infarction metalyse tenecteplase fibrinolytic treatment acute myocardial infarction hypertension catapresan clonidine treatment hypertension catapres clonidine hydrochloride catapressan cataprestts hypertension motens lacidipine treatment hypertension boehringer ingelheim annual report cardiovascular metabolic diseases continued diabetes overall around half deaths people type diabetes type diabetes chronic progressive condition associated caused concomitant cardiovascular disease indicating elevated blood sugar levels cause longterm high unmet medical need complications treated estimated four million deaths worldwide every year linked directly longterm addition cardiovascular disease serious complications effects diabetes type diabetes common form diabetes include disease accounts cases developed world currently million people nephropathy culminating renal failure requiring dialysis world live diabetes represents enormous retinopathy potential loss vision burden health care systems globally without effective pre peripheral neuropathy risk developing foot ulcers vention management strategies estimated potentially requiring foot leg amputations number cases reach million autonomic neuropathy cause gastrointestinal genitourinary cardiovascular symptoms addition type diabetes one major risk factors exual dysfunction cardiovascular disease life expectancy people type diabetes high cardiovascular risk decreases average years product portfolio human pharmaceuticals indications brand names active ingredients type diabetes mellitus trajenta linagliptin treatment adults type diabetes tradjenta mellitus adjunct diet exercise trazenta improve glycaemic control used mono therapy metformin tolerated trayenta contraindicated combination therapy type diabetes mellitus jentadueto linagliptin metformin hydrochloride treatment adults type diabetes trayenta duo mellitus adjunct diet exercise trajenta duo improve glycaemic control treatment metformin lead sufficient trajentamet control patients treated trajenta linagliptin metformin type diabetes mellitus jardiance empagliflozin treatment adults type diabetes jardianz mellitus adjunct diet exercise improve glycaemic control reduce risk cardiovascular death adults type diabetes mellitus established cardiovascular disease usa indication december label varies country please refer local product information type diabetes mellitus synjardy empagliflozin treatment adults type diabetes jardiance duo metformin mellitus adjunct diet exercise hydrochloride improve glycaemic control treatment empagliflozin metformin hydrochloride appropriate usa indication december label varies country please refer local product information type diabetes mellitus glyxambi empagliflozin linagliptin treatment adults type diabetes mellitus adjunct diet exercise improve glycaemic control adults type diabetes mellitus empagli flozin linagliptin appropriate treat ments usa indication march label varies coun try please refer local product information diabetes portfolio collaboration eli lilly company boehringer ingelheim annual report oncology cancer threat global health estimated recently however incidence lung cancer among million new cases cancer diagnosed worldwide nonsmokers increased lung cancer poor prognosis million people died cancer nearly one six global million deaths per year representing nearly deaths world cancer factsheet com cancer deaths lung cancer symptoms unspecific mon diagnosed cancer types lung cancer nearly disease may take many years appear late diagnosis breast cancer nearly colorectal cancer prostate advanced stage disease results often dismal cancer stomach cancer prognosis lung cancer patients surviving five years following diagnosis lung cancer lung cancer refers malignant abnormal cell growth inside lung cancer one disease different lung tissue forming cluster tumour com subtypes small cell lung cancer sclc nonsmall mon cancer estimated million new cases per year cell lung cancer nsclc ten different molecular worldwide smoking primary cause dis genetic aberrations mutations present tumour ease contributing almost cases identified focusing molecular changes specific respective subtype lung cancer targeted ther apies become effective treatments show survival benefit time less harmful normal cells thereby reducing side effects product portfolio human pharmaceuticals indications brand names active ingredients nonsmall cell lung cancer giotrif afatinib firstline treatment patients meta nsclc gilotrif static nonsmall cell lung cancer nsclc whose tumours activating epidermal growth factor receptor egfr mutations treatment patients locally advanced metastatic nsclc squamous histology progressing platinum based chemotherapy nonsmall cell lung cancer vargatef nintedanib combination therapy docetaxel nsclc treatment adult patients locally advanced metastatic local nonsmall cell lung cancer nsclc adenocarcinoma tumour histology firstline chemotherapy boehringer ingelheim annual report diseases central nervous system mental neurological diseases depression par restless legs syndrome rls kinsons disease significantly impact patients fami restless legs syndrome rls common neurological disor lies also substantial burden society der characterised uncontrollable urge move legs primarily occurring evening night hours usually parkinsons disease accompanied unpleasant sometimes painful sensa parkinsons disease pd degenerative disorder cen tions legs well disturbed sleep resulting daytime tral nervous system patients usually notice motor symptoms tiredness sleepiness sensations felt deep within like hand tremor shaking first sign disease legs described creeping crawling aching may progress include shaking arms legs head motor symptoms may develop time include stiffness often results loss facial expression gradual slowing loss motion freezing patients also suffer nonmotor symptoms associated pd depression sleep disorders primary symptoms result lack neuro transmitter dopamine distinct areas human brain infectious diseases hiv infectionaids acquired immune deficiency syndrome aids set symp toms infections resulting damage human immune system caused human immunodeficiency virus hiv untreated infection hiv progressively reduces effectiveness immune system leaves individuals susceptible opportunistic infections tumours babies infected mothers risk getting virus preg nancy childbirth breastfeeding product portfolio human pharmaceuticals indications brand names active ingredients parkinsons disease pd sifrol pramipexole symptomatic treatment idiopathic parkin restless legs syndrome rls mirapex sons disease may used monother mirapexin apy combination levodopa symp tomatic treatment idiopathic moderate pexola severe restless legs syndrome sleep disorders lendormin brotizolam shortterm treatment disorders initiat ing maintaining sleep insomnia requiring pharmacological inter vention indications brand names active ingredients hivaids viramune nevirapine combination therapy hiv infec viramune xr tion several countries pre vention mothertochild transmission hiv pregnant women taking antiretroviral therapy time labour prolonged release tablets oncedaily dosing within combination therapy hivaids aptivus tipranavir indicated combination antiretroviral treatment hivinfected patients co administered mg ritonavir treatmentexperienced infected hiv strains resistant one protease inhibitor boehringer ingelheim annual report livestock swine infectious respiratory diseases infectious enteric diseases ingelvac circoflex first singledose piglet vaccine enterisol ileitis first oral live vaccine control porcine circovirus disease pcvd vaccine ileitis globally prevalent enteric disease swine provides significant reduction mortality acute phase caused lawsonia intracellularis licensed improve pcvd well improved growth rates chronic phase weight gain reduce growth variability associated disease ingelvac circoflex protects minimal disease enterisol ileitis helps reduce total anti systemic adverse reactions injection site swellings microbial use pork production used gestation lactation ingelvac prrs products licensed active immunisation respiratory reproductive form porcine reproductive respiratory syndrome prrs ingelvac mycoflex provides proven safety efficacy rapid onset longlasting immunity mycoplasma hyo pneumoniae hyo single dose ingelvac mycoflex contains impranflex adjuvant allows fresh mix ing ingelvac c ircoflex form flexcombo ingelvac provenza protects multiple iavs strains decreases nasal shedding providing protection pigs vulnerable product portfolio animal health indications brand names active ingredients infectious respiratory ingelvac circoflex recombinant vaccine active immunisation pigs diseases porcine circovirus age two weeks porcine circovirus type pcv type reduce mortality clinical signs including weight loss lesions lymphoid tissues associated porcine circovirus diseases pcvd addition vaccination shown reduce pcv nasal shedding viral load blood lymphoid tissues duration viraemia infectious respiratory ingelvac prrs mlv attenuated live vaccine depending product active diseases ingelvac prrsflex eu prrs virus type type immunisation pigs various ages reprocyc prrs eu porcine reproductive respiratory syndrome virus prrsv infectious respiratory ingelvac mycoflex inactivated vaccine active immunisation pigs diseases mycoplasma age three weeks reduce lung lesions hyopneumoniae following infections mycoplasma hyo pneumoniae infectious respiratory ingelvac provenza attenuated live influenza vaccine vaccination pigs one day age diseases laiv older influenza virus strains hn hn infectious enteric diseases enterisol ileitis attenuated live vaccine active immunisation pigs lawsonia age three weeks intestinal lesions intracellularis caused lawsonia intracellularis infection reduce growth variability loss weight gain associated disease boehringer ingelheim annual report livestock cattleruminants cattleruminants business global leader antiparasitic brands ivomec longrange eprinex world renowned parasiticides treat protect grazing animals harmful effects internal external parasites zactran treats cattle bacterial pneumonia sheep digital dermatitis infections bovela active immunisation cattle three months age terms reproductive infectious diseases product portfolio animal health indications brand names active ingredients internal external ivomec ivermectin depending formulation product parasites cattle treatment nematodes lice mites ticks flies lungworms liver flukes internal external longrange eprinomectin longacting theraphase technology used develop parasites cattle formulation eprinomectin allows single treatment last days long enough break parasite life cycle effectively reduce parasite burdens pasture longrange effective control internal external parasites cattle gastrointestinal roundworms lungworms grubs mites internal external eprinex eprinomectin depending formulation product parasites ruminants treatment nematodes lice mites ticks flies lungworms cattle sheep bacterial causes respiratory zactran gamithromycin depending species indication country disease interdigital registration product treatment dermatitis footrot metaphylaxis control respiratory disease cattle caused key bacteria mannheimia pasteurella histophilus mycoplasma footrot disease sheep caused key bacteria fusobacterium dichelobacter reproductive infectious bovela bovine viral diarrhoea bvd reduces hyperthermia minimises reduc diseases cattle types tion leukocyte count caused bovine viral diarrhoea virus bvdv bvdv reduces virus shedding viraemia caused bvdv prevents birth persistently infected calves caused transplacental infection boehringer ingelheim annual report livestock cattleruminants continued vaccine pyramidpresponse part ex panding portfolio respiratory reproductive vaccines prevent diseases affect livestock metacam nonsteroidal antiinflammatory drug nsaid helping minimise losses inflammation tissue dam age animals suffering disease hence addressing need maintained profitability concern farm ani mal wellbeing product portfolio animal health indications brand names active ingredients infectious respiratory pyramid family multivalent vaccine combi pyramidpresponse family vaccines diseases reproductive presponse nations including different modified provides broad coverage bvd types disorders cattle live viruses bovine viral diarrhoea ibr brsv pi mannheimia haemolytica bvd types infectious single dose contain bovine rhinotracheitis ibr parain metastim adjuvant system enhance fluenza pi bovine respira animals response greater protection us tory syncytial virus brsv canada bacteria pasteurella multocida metastim registered trademark zoetis ervices llc mannheimia haemolytica l canic ola l grippotyphosa l hardjo l icterohaemmorrhagiae l pomona pain inflammatory metacam meloxicam treatment mastitis lactating cows disorders control pain associated dehorning surgery also indicated use calves affected diarrhoea cattle suffering respiratory disease boehringer ingelheim annual report livestock poultry poultry vaccine portfolio consists significant range live inactivated vaccines broilers layers breeder hens providing protection critical viral bacterial diseases like avian influenza infectious bronchitis newcastle disease infectious bursal disease egg drop syndrome avian coryza portfolio preventive pro ducts helps producers worldwide provide safe affordable abundant sustainable highquality poultry meat eggs product portfolio animal health indications brand names active ingredients various viral bacterial gallimune polyvalent attenuated live vaccination healthy chickens diseases poultry gallivac inactivated vaccine containing diseases caused included antigens volvac antigens vaccination prevention common diseases avian influenza broiler chickens diseases responsible newcastle disease avian losses egg production layers coryza egg drop syndrome infectious bronchitis infectious bursal disease gallibacterium anatis infectious bursal disease vaxxitekhvt ibd serotype live mareks prevent mortality reduce clinical mareks disease disease vector live vhvt signs lesions infectious bursal disease r ecombinant virus onset protection two weeks diluent protection extends nine weeks reduce mortality clinical signs lesions mareks disease onset protection four days single vaccination sufficient provide reliable protection risk period newcastle disease nd avinew live newcastle disease virus broiler chickens one day age active vggaavinew strain immunisation newcastle disease reduce mortality clinical signs associated disease future layer future breeder pullets age four weeks priming active immu nisation egg drop caused newcastle disease vaccination inactivated vaccine strain ulster c prior beginning lay mareks disease prevexxiontm rn live herpes virus chimera vaccine recommended ovo vacci serotype nation dayold embryonated strain rn chicken eggs protect virulent mareks disease newcastle mareks newxxitektm hvtnd live mareks disease vectored vaccination dayold embryos iseases virus serotype contains onedayold chickens effective gene insert newcastle mareks disease newcastle disease disease vaccine includes diluent boehringer ingelheim annual report veterinary public health vph work governments private partners towards btv pur multistrain vaccine used active immunisation improving control eradicating diseases footand sheep cattle prevent viraemia reduce clinical mouth disease bluetongue virus rabies signs caused bluetongue virus footandmouth vaccines portfolio works active immunisation cattle sheep pigs reduce clinical signs mortality following exposure footandmouth disease fmd virus rabisin inactivated vaccine rabies available clear colourless suspension injection product portfolio animal health indications brand names active ingredients footandmouth disease aftopor mix inactivated fmd virus fmd vaccines highly potent purified fmd aftovaxpur antigens widest range antigens aftopor aftovaxpur aftobov aftovax vaccine strains oleosa potential marker properties allow differentiation infected aftobov oleosa vaccinated animals diva endemic aftovaxpur doe emergency situations aftovaxpur doe suitable emergency ituations r abies rabisin rabisin inactivated adjuvanted rabisin used active immunisation raboral vrg rabies glycoproteins dogs cats reduce mortality clinical raboral vrg vaccinavectored signs due rabies infection immunity rabies vaccine demonstrated one month vaccina tion shown persist next revaccination dose raboral vrg oral rabies recombinant vaccine protects raccoons coyotes rabies thereby reducing risk exposure rabies humans domestic animals sold government agencies conducting rabies control programs b luetongue btv pur mix inactivated bluetongue virus active immunisation sheep prevent virae mia reduce clinical signs caused bluetongue virus serotypes andor combination maximum serotypes active immunisation cattle prevent virae mia caused bluetongue virus serotypes andor reduce clinical signs caused bluetongue virus serotypes andor combination maximum serotypes onset immunity demonstrated three weeks five weeks sheep btv primary vaccination course btv btv cattle btv btv serotypes boehringer ingelheim annual report companion animals horse main horse products focus prevention treat gastrogard ulcergard indicated treatment ment parasite infestations management solutions prevention equine gastric ulcers one chronic diseases vaccines equine portfolio also common diseases horses gastrogard sup includes range flagship products treatment joint plied easytouse oral paste form first disease colic respiratory disease pain management choice treatment gastric ulcers since launch nutraceuticals ulcergard usa preventive choice horses increased risk developing gastric ulcers prascend indicated treatment pituitary pars intermedia dysfunction ppid also known equine eqvalanzimecterin contains ivermectin leading ingredi cushings disease clinical signs ppid hypertrichiosis ent controls wide variety important internal parasites laminitis change body conformation lack perform including bots benzimidazoleresistant small strongyles ance treatment prascend lifelong easytoadminister oral paste eqvalanzimecterin approved adult horses foals young six weeks age vetera vaccines first us vaccine portfolio include multiple convenient combinations disease protection eqvalan duogold zimecterin gold combines ivermectin horses young four months age vaccines pro praziquantel ingredient specifically controls tect many nine infectious organisms including tapeworms influenza herpes west nile virus tetanus others enables customised protection horse limited needle injections product portfolio animal health indications brand names active ingredients pituitary pars intermedia prascend pergolide mesylate symptomatic treatment clinical signs associ dysfunction ppid ated pituitary pars intermedia dysfunction ppid also known equine cushings disease combination vaccine vetera eastern western venezuelan vaccination healthy horses aid nine common diseases encephalomyelitis tetanus west prevention diseases caused horses nile virus equine included antigens us canada herpes virus equine influenza viruses equine gastric ulcers gastrogard omeprazole treatment prevention gastric ulcers ulcergard prevention recurrence gastric ulcers horses foals four weeks age older internal parasites eqvalan ivermectin treatment prevention parasitic infes zimecterin ivermectin praziquantel tations horses donkeys due large eqvalan gold small strongyles ascarids eqvalan duo zimecterin gold goldduo includes treatment tape worms boehringer ingelheim annual report companion animals pets pets portfolio offers diverse solutions heartgard plus contains active ingredients ivermectin important needs canine feline health including indus pyrantel soft beef chew given monthly tryleading parasiticides vaccines therapeutics address ivermectin effective preventing deadly heartworm dis major chronic diseases heart failure kidney diseases hyper ease pyrantel effective treatment control round tension epilepsy osteoarthritis worms well hookworms heartgard launched first monthly heartworm preventative still years frontline leader flea bestselling heartworm preventative world tick control dogs cats one trusted brands animal health frontline continues broadline offers pet owners allinone convenience providing bring innovation category recent launch confidence cat broadest possible protection frontline triact features repellency insecticidal protects cats broadest spectrum internal efficacy many diseasecarrying flying insects external parasites including adult fleas flea eggs flea larvae decreases risk transmission vectorborne pathogen ticks heartworms hookworms roundworms tapeworms nexgard contains active ingredient afoxolaner first new class heart treatments termed inodilators first oral medication treats fleas ticks dogs vetmedin shown significantly improve clinical efficacy palatable beefflavoured soft chew signs extend life expectancy dogs congestive heart formulation nexgard currently bestselling pet medi failure originating dilated cardiomyopathy valvular insuf cation animal health industry ficiency mitral andor tricuspid regurgitation recent studies also shown used preclinically appropriate nexgard spectra combines flea tick efficacy asymptomatic cases either dilated cardiomyopathy dober afoxolaner nexgard broadspectrum deworming man pinschers valvular insuffi ciency vetmedin significantly ingredient milbemycin oxime beefflavoured delays onset clinical signs congestive heart failure chew nexgard spectra effective treating fleas ticks also protects dogs deadly parasites heartworm lungworm well gastrointestinal parasites data file novel combination fipronil permethrin frontline triactfrontect reduces risk transmission babesia canis dermacentor reticulatus ehrlichia canis rhipicephalus sanguineus ticks dogs jongejan et al parasites vectors data file data file product portfolio animal health indications brand names active ingredients antiparasitic caninefeline frontline fipronil frontline indicated treatment external parasites frontline combo fipronilsmethoprene prevention fleas ticks chewing lice frontline plus fipronilpermethrin dogs cats aids control frontline triact frontect sarcoptic mange dogs frontline plus frontline combo indi cated treatment prevention fleas ticks chewing lice dogs cats also breaks flea life cycle preventing development immature stages aids control sarcoptic mange dogs frontline triactfrontect indicated treatment prevention flea tick infestations repellent antifeeding activity necessary sandflies biting flies andor mosquitos dogs antiparasitic canine external nexgard afoxolaner nexgard delivered highly palatable parasites beefflavoured chew kills adult fleas indicated treatment prevention flea infestations treatment control tick infestations dogs puppies one month antiparasitic canine internal nexgard spectra afoxolaner nexgard spectra delivered highly external parasites milbemycin oxime palatable beefflavoured chew kills adult fleas indicated treatment prevention flea tick infestations prevents heartworm disease treats controls hookworm roundworm whipworm lung worm infestations dogs puppies antiparasitic canine internal heartgard plus ivermectin use dogs prevent canine heartworm parasites pyrantel disease eliminating tissue stage heartworm larvae month days infection treatment control roundworms hookworms antiparasitic feline internal broadline fipronil smethoprene protects cats broadest spectrum external parasites eprinomectin praziquantel internal external parasites including adult fleas flea eggs flea larvae ticks heartworms hookworms roundworms tapeworms congestive heart failure vetmedin pimobendan treatment canine congestive heart failure originating dilated cardio myo pathy valvular insufficiency mitral andor tricuspid regurgitation treatment dilated cardiomyopathy preclinical stage asymptomatic increase left ventricular endsystolic enddiastolic diameter doberman pinschers treatment dogs myxomatous mitral valve disease mmvd preclinical stage asymptomatic systolic mitral murmur evidence increased heart size delay onset clinical symptoms heart failure boehringer ingelheim annual report companion animals pets continued metacam nonsteroidal antiinflammatory drug nsaid pet vaccine product portfolio includes purevax feline available oral suspension tablets injectable vaccines formulated provide effective protection without solution dogs oral suspension injectable use adjuvants recombitek providing targeted pro solution cats dogs indications include allevia tection dogs recombinant technology tion inflammation pain acute chronic mus culoskeletal disorders well reduction pain follow ing surgery cats indications include alleviation inflammation pain acute chronic musculoskeletal disorders well alleviation mild moderate postoperative pain variety formulations offers veteri narians owners flexibility use formulation prefer individual cases manage various levels inflammation pain associated licensed indications semintra firstever licensed angiotensin receptor blocker arb veterinary use provides proven convenient safe compliance solution cats cat owners vets semintra available mgml mgml oral solution semintra mgml first launched reduc tion proteinuria associated chronic kidney disease ckd cats semintra mgml launched control ustreatment eu feline systemic hypertension first vetlicensed product feline hypertension us product portfolio animal health indications brand names active ingredients p inflammatory metacam meloxicam dogs metacam used reduce post diseases operative pain inflammation following orthopaedic eg fracture operation soft tissue surgery cats metacam used reduce postopera tive pain inflammation eg ovario hysterectomy spay operation orthopaedic minor soft tissue surgery moreover used alleviation pain inflammation acute chronic muscu loskeletal disorders dogs cats chronic kidney disease ckd semintra telmisartan mgml management chronic kidney dis cats ease ckd cats reduction proteinuria associated ckd cats hypertension cats mgml hypertension indicated treatment eucontrol us feline systemic hypertension feline vaccines portfolio purevax feline herpes virus purevax fully adjuvantfree feline feline calicivirus vaccine range provides feline panleukopenia virus optimised safety profile adjuvantfree chlamydophila felis protection components recombinant vectored feline leukemia virus powerful immune response without adju recombinant vectored rabies virus vant thanks innovative canarypox technology felv rabies easy fit cat lifestyles allow ing com pliance feline vaccination guidelines sustained protection three years rabies component canine vaccines portfolio recombitek recombinant vectored canine dis recombitek offers complete line canine us others temper virus vaccines canine parvovirus proven efficacy distemper canine adenovirus type presence maternal antibodies canine parainfluenza virus coronavirus concentrated parvo demonstrated leptospira canicola protection major circulating strains leptospira grippotyphosa cpva b c leptospira icterohaemorrhagiae prevention disease shedding leptospira pomona leptospirosis recombinant borrelia burgdorferi bordetella bronchiseptica targeted advanced science without need adjuvants recombitek lyme vaccine contains ospa nonadjuvant formulation rekombitek oral bordatella effective safe protection made easy data fileboehringer ingelheim annual report ch boehringer sohn ag co kg ingelheim comparison balance sheet financial data eur million assets december intangible assets tangible assets financial assets fixed assets inventories accounts receivable assets incl prepaid expenses deferred taxes exceeding amount plan assets liquid funds current assets total assets equity liabilities december shareholders capital group reserves incl balance sheet currency conversion difference group profit equity attributable parent company noncontrolling interests group equity difference capital consolidation provisions incl deferred taxes liabilities incl deferred income total liabilities incl deferred taxes deferred income total equity liabilities summary selected financial data net sales operating income operating income net sales income taxes income taxes net sales return equity equity ratio cash flow operating activities financial funds personnel expenses personnel expenses net sales average number employees research development expenses rd expenses net sales investments tangible assets depreciation tangible assets p r n ch boehringer sohn ag co kg assets december binger strae intangible assets ingelheim germany tangible assets telephone financial assets fax fixed assets contact inventories corporate division communications public affairs accounts receivable assets incl prepaid expenses email pressboehringeringelheimcom deferred taxes exceeding amount plan assets internet wwwboehringeringelheimcom liquid funds issued current assets ch boehringer sohn ag co kg total assets concept design layout equity liabilities december mpm corporate communication solutions mainz dsseldorf wwwmpmde shareholders capital group reserves incl balance sheet currency conversion difference photos group profit andreas pohlmann andreas reeg equity attributable parent company noncontrolling interests printed group equity eberl print gmbh immenstadt difference capital consolidation copyright provisions incl deferred taxes ch boehringer sohn ag co kg liabilities incl deferred income rights reserved part annual report may reproduced transmitted form means total liabilities incl deferred taxes deferred income electronic photocopy without permission writing total equity liabilities ch boehringer sohn ag co kg figures third parties used annual report based data available time financial statement drawn summary selected financial data net sales operating income operating income net sales income taxes income taxes net sales return equity equity ratio cash flow operating activities financial funds personnel expenses personnel expenses net sales average number employees research development expenses rd expenses net sales investments tangible assets depreciation tangible assets wwwboehringeringelheimcom annualreportboehringeringelheimcom